Data / Research funding / Infectious Diseases
Infectious Diseases: 20,139 NIH awards ($32.8B) to 1,516 organizations
20,139 NIH awards ($32.8B) in the NIH spending category Infectious Diseases, to 1,516 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 20,139 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $965,792,899 | June 15, 2020 | June 30, 2026 | THOMAS, SONIA M | reporter.nih.gov |
| OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $650,978,035 | May 24, 2021 | May 23, 2025 | KATZ, STUART D | reporter.nih.gov |
| Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $472,070,715 | December 1, 2024 | November 30, 2025 | CURRIER, JUDITH S. | reporter.nih.gov |
| NIAID HIV and Other Infectious Diseases Clinical Research Support Services (CRSS) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $417,904,831 | August 15, 2023 | August 14, 2024 | STROKES, BAMBRA | reporter.nih.gov |
| HIV Vaccines Clinical Trials Network Leadership and Operations Center | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $244,071,463 | June 29, 2006 | November 30, 2027 | COREY, LAWRENCE | reporter.nih.gov |
| HIV Prevention Trials Network Leadership and Operations Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $213,590,410 | June 1, 2006 | November 30, 2027 | COHEN, MYRON SCOTT | reporter.nih.gov |
| HIV and Other Infectious Diseases Clinical Research Support Services (CRSS) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $198,645,463 | August 15, 2025 | August 14, 2026 | STOKES, BAMBRA | reporter.nih.gov |
| HIV Vaccine Trials Network Laboratory Center | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $177,480,054 | June 29, 2006 | November 30, 2027 | MCELRATH, MARGARET JULIANA | reporter.nih.gov |
| SDMC: HIV Vaccine Trials Network | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $156,744,802 | June 29, 2006 | November 30, 2027 | GILBERT, PETER B. | reporter.nih.gov |
| CoVPN LOC Cross-Protocol Infrastructure Supplement for GY15 and GY16 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $156,469,927 | March 30, 2022 | March 31, 2022 | COREY, LAWRENCE | reporter.nih.gov |
| Statistical and Data Coordinating Center (SDCC) for Clinical Research in Infectious Diseases: Mpox Clinical Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $150,331,625 | March 1, 2021 | February 28, 2026 | EWELL, MARIAN | reporter.nih.gov |
| Consortium for HIV/AIDS Vaccine Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $145,502,241 | July 1, 2019 | June 30, 2026 | BURTON, DENNIS R. | reporter.nih.gov |
| Induction of protective antibodies for HIV vaccine development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $143,048,158 | July 15, 2019 | June 30, 2026 | HAYNES, BARTON F. | reporter.nih.gov |
| Consortium for Advancing Management and Prevention of Cancer in People with HIV | NIH | National Cancer Institute | 2021 to 2025 | $106,635,299 | August 29, 2006 | August 31, 2030 | SPARANO, JOSEPH A. | reporter.nih.gov |
| RADx-UP CDCC | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2023 | $96,490,468 | September 27, 2020 | June 30, 2025 | COHEN-WOLKOWIEZ, MICHAEL | reporter.nih.gov |
| NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE: AVIAN INFLUENZA RESEARCH | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $91,354,067 | April 1, 2021 | January 14, 2027 | WEBBY, RICHARD | reporter.nih.gov |
| AI-driven Structure-enabled Antiviral Platform (ASAP) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $89,845,851 | May 16, 2022 | August 31, 2027 | CHODERA, JOHN DAMON | reporter.nih.gov |
| CLINICAL RESEARCH OPERATIONS AND MANAGEMENT SUPPORT (CROMS) - SARS CoV-2 Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $86,825,316 | April 17, 2017 | April 16, 2024 | HOLMES, MELYNDA | reporter.nih.gov |
| Statistical and Data Management Center (SDMC), Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $84,840,845 | June 29, 2006 | November 30, 2027 | HUGHES, MICHAEL DAVID | reporter.nih.gov |
| Antibacterial Resistance Leadership Group (ARLG) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $78,031,274 | June 1, 2013 | November 30, 2026 | FOWLER, VANCE G. | reporter.nih.gov |
| IMPAACT Leadership Group | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $77,468,129 | December 1, 2024 | November 30, 2027 | NACHMAN, SHARON A | reporter.nih.gov |
| HPTN SDMC: HPTN 096 Getting to Zero among Highest HIV Incidence (HHI) Men who have Sex with Men (MSM) in the American South: Testing an Integrated Strategy | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $74,729,762 | June 29, 2006 | November 30, 2027 | DONNELL, DEBORAH J | reporter.nih.gov |
| COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $72,825,966 | September 10, 2019 | September 24, 2026 | KRAMMER, FLORIAN | reporter.nih.gov |
| Pediatric HIV/AIDS Cohort Study (PHACS) 2020 | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $71,153,847 | September 18, 2020 | July 31, 2026 | WILLIAMS, PAIGE L | reporter.nih.gov |
| NIA AD/ADRD Health Care Systems Research Collaboratory | NIH | National Institute on Aging | 2021 to 2025 | $69,169,841 | September 1, 2019 | August 31, 2030 | MOR, VINCENT | reporter.nih.gov |
| NIAID CLINICAL SITE MONITORING | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $68,539,045 | February 1, 2023 | January 31, 2024 | SMITH, KIMBERLY | reporter.nih.gov |
| COVID-19: NIAID Regulatory Support Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $63,227,516 | April 15, 2023 | April 14, 2024 | RAFI, ASIMAH | reporter.nih.gov |
| Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $63,155,364 | December 5, 2019 | November 30, 2026 | STEPHENS, DAVID S | reporter.nih.gov |
| Microbiology and Infectious Diseases Biological Resource Repository (MID-BRR) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $63,039,784 | May 5, 2022 | October 31, 2023 | WILLIAMS, CARLA | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $62,580,113 | April 1, 2021 | September 17, 2026 | GARCIA-SASTRE, ADOLFO | reporter.nih.gov |
| Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $61,029,344 | September 30, 2019 | March 31, 2027 | URDAHL, KEVIN | reporter.nih.gov |
| SDMC - IMPAACT Leadership Group | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $59,233,299 | June 29, 2006 | November 30, 2027 | SHAPIRO, DAVID ERIC | reporter.nih.gov |
| CoVPN 5001 - A prospective study of acute immune responses to SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $57,987,348 | March 21, 2022 | March 31, 2022 | GILBERT, PETER B. | reporter.nih.gov |
| AIDS Clinical Trial Group Laboratory Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $56,714,107 | January 1, 2014 | November 30, 2027 | ALDROVANDI, GRACE M | reporter.nih.gov |
| HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $54,331,950 | March 18, 2022 | March 31, 2022 | MCELRATH, MARGARET JULIANA | reporter.nih.gov |
| CIVIC: University of Georgia Center for Influenza Vaccine Research in High Risk Populations | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $53,879,677 | September 10, 2019 | September 9, 2026 | ROSS, TED | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $52,452,735 | September 10, 2019 | September 9, 2026 | MOODY, TONY | reporter.nih.gov |
| Tulane National Primate Research Center | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $52,341,995 | May 9, 1997 | April 30, 2028 | HAMM, L LEE | reporter.nih.gov |
| CEIRR: CORONAVIRUS RESEARCH ACTIVITIES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $50,650,417 | April 1, 2021 | September 29, 2026 | HENSLEY, SCOTT | reporter.nih.gov |
| DMID Clinical Research Operations & Management Support (CROMS): mpox activities | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $47,983,949 | April 1, 2024 | March 31, 2026 | ELLIS, JESSICA | reporter.nih.gov |
| SUPPORT SERVICES OF THE HIV AIDS CLINICAL TRIAL NETWORKS | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $45,166,816 | November 30, 2022 | November 29, 2025 | DRIVER, BARBARA | reporter.nih.gov |
| Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $44,959,734 | August 13, 2025 | November 30, 2026 | KOTLOFF, KAREN L. | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component B: Vaccine Manufacturing and Toxicology Core | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $44,296,051 | August 26, 2019 | March 13, 2028 | DENNY, THOMAS | reporter.nih.gov |
| Biological and Emerging Infections Research Resources Program (BEI-RRP): HIV/AIDS | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $44,214,194 | October 16, 2023 | October 15, 2025 | RASHID, SUJATHA | reporter.nih.gov |
| LC: HIV PREVENTION TRIALS NETWORK | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $40,489,166 | June 1, 2006 | November 30, 2027 | ESHLEMAN, SUSAN H | reporter.nih.gov |
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $39,144,749 | September 1, 1998 | August 31, 2027 | PARK, BEN HO | reporter.nih.gov |
| Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $38,435,039 | September 30, 2019 | September 29, 2026 | FORTUNE, SARAH | reporter.nih.gov |
| Vanderbilt Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $36,564,580 | December 11, 2019 | November 30, 2026 | CREECH, CLARENCE BUDDY | reporter.nih.gov |
| Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Scientific Leadership Center | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $36,023,354 | January 25, 2023 | January 14, 2030 | HIGHTOW-WEIDMAN, LISA B | reporter.nih.gov |
| Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $35,184,139 | August 1, 2021 | July 31, 2026 | COLER, RHEA | reporter.nih.gov |
| Cancer Center Support Grant (CCSG) | NIH | National Cancer Institute | 2021 to 2025 | $35,080,297 | April 1, 1997 | February 28, 2026 | ROBERTS, CHARLES | reporter.nih.gov |
| Production of Aluminum Based Adjuvants | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $34,078,534 | September 20, 2017 | December 31, 2026 | MACK, FRED | reporter.nih.gov |
| CFAR Network of Integrated Clinical Systems (CNICS) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $32,404,861 | September 30, 2006 | August 31, 2026 | SAAG, MICHAEL S. | reporter.nih.gov |
| Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $32,243,461 | September 22, 2022 | October 9, 2029 | MEGAZZINI, KAREN | reporter.nih.gov |
| West Virginia Clinical and Translational Science Institute: A Statewide Organization Building Research Excellence and Engaging Communities to Improve Health | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $31,832,071 | August 15, 2012 | June 30, 2027 | HODDER, SALLY LYNN | reporter.nih.gov |
| SECURE PLATFORMS SUPPORT FOR THE N3C DATA ENCLAVE (COVID-19) | NIH | National Institute on Drug Abuse | 2021 to 2023 | $30,357,494 | August 2, 2023 | September 24, 2023 | MARIZAN-HO, JOHANNA | reporter.nih.gov |
| Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney Collaboratory | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $30,092,882 | August 16, 2021 | April 30, 2027 | PERSAUD, DEBORAH | reporter.nih.gov |
| DIVINCI: Dissection of Influenza Vaccination and Infection for Childhood Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $30,010,720 | May 2, 2019 | April 30, 2027 | WEBBY, RICHARD JOHN | reporter.nih.gov |
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $29,642,385 | September 12, 1997 | November 30, 2025 | RATHMELL, WENDY KIMRYN | reporter.nih.gov |
| FOLLOW-UP AND EXTENDED FOLLOW-UP OF PARTICIPANTS | NIH | National Cancer Institute | 2021 to 2025 | $29,487,084 | April 6, 2018 | September 15, 2026 | PORRAS, CAROLINA | reporter.nih.gov |
| BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $29,083,069 | August 16, 2021 | April 30, 2027 | MONTANER, LUIS J | reporter.nih.gov |
| Case Comprehensive Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $28,812,474 | August 1, 1997 | March 31, 2030 | SCHWARTZ, GARY K | reporter.nih.gov |
| Task V15: Development of Assays and Reagents for mpox Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $28,751,383 | September 1, 2022 | April 30, 2026 | RUDGE, THOMAS | reporter.nih.gov |
| RADX-TECH - LUMINOSTICS, INC. SMARTPHONE-BASED TEST FOR RAPID SARS-COV-2 ANTIGEN DETECTION FROM NASAL SWABS | NIH | National Heart, Lung, and Blood Institute | 2021 | $28,624,460 | September 30, 2020 | September 29, 2021 | RAJA, BALA | reporter.nih.gov |
| STSS: SMART IRB ONLINE RELIANCE SYSTEM (ORS) AND JOINDER ENHANCEMENTS SUPPORT SERVICES | NIH | National Institute on Drug Abuse | 2021 to 2022 | $27,880,093 | April 15, 2022 | April 14, 2023 | MAYS, GARY | reporter.nih.gov |
| Task D02: Pre-Clinical Pharmacokinetic Services | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $27,852,554 | February 25, 2019 | February 24, 2020 | MIRSALIS, JON | reporter.nih.gov |
| REACH: Research Enterprise to Advance a Cure for HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $27,533,114 | August 16, 2021 | April 30, 2027 | JONES, R. BRAD | reporter.nih.gov |
| Northern New England Clinical and Translational Research Network | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $27,379,043 | July 3, 2017 | June 30, 2027 | ROSEN, CLIFFORD JAMES | reporter.nih.gov |
| HOPE - HIV Obstruction by Programmed Epigenetics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $27,293,591 | August 16, 2021 | April 30, 2027 | OTT, MELANIE MARIA | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response (CEIRR): Avian Influenza Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $27,250,171 | April 1, 2021 | January 14, 2027 | LOWEN, ANICE | reporter.nih.gov |
| Delaney AIDS Research Enterprise to Cure HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $26,967,938 | August 16, 2021 | April 30, 2027 | DEEKS, STEVEN GRANT | reporter.nih.gov |
| The DC Cohort: A Longitudinal Population-Based Cohort Study of People Living with HIV in Washington, DC | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $26,415,291 | June 1, 2020 | June 30, 2030 | CASTEL, AMANDA DERRYCK | reporter.nih.gov |
| B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $26,314,793 | June 1, 2022 | May 31, 2027 | HUNTER, ERIC | reporter.nih.gov |
| The Florida Node Alliance of the National Drug Abuse Clinical Trials Network (CTN-121) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $26,301,696 | March 1, 2025 | February 29, 2028 | SZAPOCZNIK, JOSE | reporter.nih.gov |
| Collaboratory of AIDS Researchers for Eradication (CARE) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $26,234,170 | August 16, 2021 | April 30, 2027 | MARGOLIS, DAVID M. | reporter.nih.gov |
| Louisiana Clinical and Translational Science Center | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $25,457,946 | August 15, 2012 | June 30, 2027 | KIRWAN, JOHN P. | reporter.nih.gov |
| ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $25,334,968 | August 16, 2021 | June 12, 2026 | PAIARDINI, MIRKO | reporter.nih.gov |
| Impact of the Initial Influenza Exposure on the Quality, Magnitude, Breadth, Potency and Durability of Influenza Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $24,789,202 | May 15, 2019 | April 30, 2027 | STAAT, MARY A | reporter.nih.gov |
| The Johns Hopkins Center for AIDS Research (JHU CFAR) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $24,770,118 | May 2, 2012 | April 30, 2027 | CHAISSON, RICHARD E. | reporter.nih.gov |
| University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $24,477,809 | February 1, 2007 | November 30, 2027 | ERON, JOSEPH J | reporter.nih.gov |
| CRISPR for Cure | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $24,038,480 | August 16, 2021 | April 30, 2027 | KHALILI, KAMEL | reporter.nih.gov |
| AIDS and Cancer Specimen Resource (ACSR) | NIH | National Cancer Institute | 2021 to 2025 | $24,013,599 | September 23, 2013 | August 31, 2026 | BETHONY, JEFFREY MICHAEL | reporter.nih.gov |
| TASK ORDER 7 - ODP | NIH | National Institute on Drug Abuse | 2024 | $23,970,498 | May 31, 2024 | September 30, 2024 | MAYS, GARY | reporter.nih.gov |
| Data Analysis and Coordination Center for the MACS-WIHS Combined Cohort Study | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $23,837,604 | April 9, 2019 | September 30, 2026 | GANGE, STEPHEN J | reporter.nih.gov |
| SDMC: HIV Prevention Trials Network | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $23,565,144 | June 29, 2006 | March 31, 2022 | DONNELL, DEBORAH J | reporter.nih.gov |
| University of Washington/Fred Hutch Center for AIDS Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $23,344,932 | March 1, 1997 | May 31, 2028 | CELUM, CONNIE L | reporter.nih.gov |
| I4C 2.0: Immunotherapy for Cure | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $23,329,181 | August 16, 2021 | April 30, 2027 | BAROUCH, DAN H. | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $23,280,590 | August 1, 2021 | January 14, 2027 | PEKOSZ, ANDREW | reporter.nih.gov |
| Division of Microbiology and Infectious Diseases (DMID): Clinical Materials Services (CMS) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $23,170,962 | September 21, 2022 | September 20, 2026 | SCHROCK, RICHARD | reporter.nih.gov |
| SF Bay Area MACS/WIHS Combined Cohort Study | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $23,128,905 | April 1, 2019 | September 30, 2026 | TIEN, PHYLLIS C | reporter.nih.gov |
| Interactions of SARS-CoV-2 infection and genetic variation on the risk of cognitive decline and Alzheimer’s disease in Ancestral and Admixed Populations | NIH | National Institute on Aging | 2023 to 2025 | $23,106,653 | August 15, 2023 | July 31, 2028 | DE ERAUSQUIN, GABRIEL ALEJANDRO | reporter.nih.gov |
| Vaccine and Treatment Evaluation Units | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $22,981,366 | December 11, 2019 | November 30, 2026 | ROUPHAEL, NADINE GEORGES | reporter.nih.gov |
| MANUFACTURE OF CLINICAL GRADE EPSTEIN-BARR VIRUS VACCINE | NIH | National Cancer Institute | 2023 to 2025 | $22,579,077 | September 22, 2025 | September 21, 2027 | reporter.nih.gov | |
| UCSF-Bay Area Center for AIDS Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $22,420,938 | March 1, 1997 | June 30, 2027 | GANDHI, MONICA | reporter.nih.gov |
| Los Angeles CRS for the MACS/WIHS Combined Cohort Study | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $22,107,486 | April 15, 2019 | September 30, 2026 | MIMIAGA, MATTHEW JAMES | reporter.nih.gov |
| University of Pittsburgh MACS/WIHS CCS | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $21,988,029 | April 1, 2019 | September 30, 2026 | RINALDO, CHARLES R | reporter.nih.gov |
| SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $21,986,953 | September 2, 2022 | June 30, 2027 | WILLIAMS, WILTON B | reporter.nih.gov |
| Chemistry Services for the Division of Translational Toxicology (HIV testing program) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $21,918,775 | July 30, 2014 | January 31, 2026 | reporter.nih.gov | |
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $21,835,693 | July 1, 2020 | August 31, 2026 | PEVEAR, DANIEL | reporter.nih.gov |
| CENTERS FOR RESEARCH ON STRUCTURAL BIOLOGY OF INFECTIOUS DISEASES | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $21,661,527 | September 1, 2022 | August 31, 2026 | STAKER, BART | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,625,203 | April 1, 2021 | September 14, 2027 | TOMPKINS, S. MARK | reporter.nih.gov |
| UZ-UCSF CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,624,239 | September 9, 2025 | November 30, 2027 | CHIRENJE, ZVAVAHERA MIKE | reporter.nih.gov |
| UCLA AIDS Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,546,764 | February 1, 2007 | November 30, 2027 | LANDOVITZ, RAPHAEL J | reporter.nih.gov |
| Boston HIV CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,445,869 | January 15, 2007 | November 30, 2027 | KURITZKES, DANIEL R. | reporter.nih.gov |
| Vaccine and Treatment Evaluation Unit at Saint Louis University | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,219,564 | December 11, 2019 | November 30, 2026 | HOFT, DANIEL F. | reporter.nih.gov |
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $21,157,224 | July 1, 2020 | January 31, 2025 | CIRZ, RYAN | reporter.nih.gov |
| Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $21,023,937 | April 1, 2019 | September 30, 2026 | SHARMA, ANJALI | reporter.nih.gov |
| Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) - Baltimore/Wash DC Center | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $21,007,836 | April 1, 2019 | September 30, 2026 | MARGOLICK, JOSEPH B. | reporter.nih.gov |
| New Mexico IDeA Networks of Biomedical Research Excellence (INBRE) | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $20,744,885 | September 30, 2001 | March 31, 2029 | LUSETTI, SHELLEY | reporter.nih.gov |
| Center for AIDS Research at Emory University-CFAR RYSE Pathway Programs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $20,704,145 | September 30, 2002 | May 31, 2027 | DEL RIO, CARLOS | reporter.nih.gov |
| CENTERS FOR RESEARCH ON STRUCTURAL BIOLOGY OF INFECTIOUS DISEASES | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $20,695,869 | September 1, 2022 | August 31, 2026 | SATCHELL, KARLA | reporter.nih.gov |
| COVID-19: External Quality Assurance Program Oversight Laboratory (EQAPOL) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $20,632,183 | September 30, 2023 | September 29, 2024 | DENNY, THOMAS | reporter.nih.gov |
| International Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $20,605,531 | January 1, 2014 | November 30, 2027 | ALDROVANDI, GRACE M | reporter.nih.gov |
| Specialized Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2024 | $20,560,271 | July 1, 1996 | April 30, 2026 | SIMEONE, DIANE M | reporter.nih.gov |
| NIAID Specimen Repository | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $20,383,408 | September 30, 2025 | September 29, 2026 | PHIPPARD, DEBORAH | reporter.nih.gov |
| BIOINFORMATICS RESOURCE CENTERS FOR INFECTIOUS DISEASES: SARS-CoV-2 ACTIVITIES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $20,255,157 | September 15, 2019 | September 14, 2024 | STEVENS, RICK | reporter.nih.gov |
| Reversing Immune Dysfunction for HIV-1 Eradication | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $20,001,273 | August 16, 2021 | October 31, 2026 | CHANDA, SUMIT K | reporter.nih.gov |
| SUPPORT SERVICES FOR THE PREVENTION AND TREATMENT THROUGH A COMPREHENSIVE CARE CONTINUUM FOR HIV-AFFECTED ADOLESCENTS IN RESOURCE CONSTRAINED SETTINGS IMPLEMENTATION SCIENCE NETWORK | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $19,936,404 | August 25, 2025 | August 24, 2026 | DRIVER, BARBARA | reporter.nih.gov |
| Northwestern CORE Clinical Research Site: Trans-omics for HIV/AIDS Research | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $19,790,656 | April 10, 2019 | September 30, 2026 | WOLINSKY, STEVEN M | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component C: Clinical Core | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $19,720,676 | September 16, 2019 | September 15, 2026 | FRANKENFIELD, JILL | reporter.nih.gov |
| Chemistry Center for Combatting Antibiotic-Resistant Bacteria (CC4CARB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $19,637,160 | February 1, 2025 | January 31, 2026 | BLOUGH, BRUCE | reporter.nih.gov |
| San Diego Center for AIDS Research (SD CFAR) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $19,569,961 | April 1, 1997 | March 31, 2028 | SMITH, DAVID MITCHELL | reporter.nih.gov |
| Vermont Biomedical Research Network-Vermont INBRE | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $19,534,463 | September 30, 2001 | June 30, 2030 | FRANCKLYN, CHRISTOPHER S | reporter.nih.gov |
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $19,528,719 | June 1, 1997 | June 30, 2028 | STEIDL, ULRICH | reporter.nih.gov |
| North American AIDS Cohorts on Collaboration and Design (NAACCORD) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $19,377,019 | July 1, 2006 | April 30, 2027 | ALTHOFF, KERI NICOLE | reporter.nih.gov |
| ADJUVANT COMPARISON AND CHARACTERIZATION | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $19,155,153 | September 1, 2022 | August 31, 2027 | PULENDRAN, BALI | reporter.nih.gov |
| BIOINFORMATICS RESOURCE CENTERS FOR INFECTIOUS DISEASES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $19,139,828 | September 15, 2019 | September 14, 2024 | ROOS, DAVID | reporter.nih.gov |
| Baylor College of Medicine Cancer Center - Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $19,034,443 | July 1, 2007 | June 30, 2030 | REDDY, PAVAN | reporter.nih.gov |
| A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $18,851,827 | September 25, 2020 | March 31, 2027 | HAVLIR, DIANE V | reporter.nih.gov |
| Third Coast Center for AIDS Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $18,823,279 | April 9, 2015 | July 31, 2030 | MUSTANSKI, BRIAN | reporter.nih.gov |
| Expanding HOPE Liver Transplantation: Understanding Opportunistic Infection and Cancer Risk | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $18,807,472 | August 1, 2018 | August 31, 2030 | DURAND, CHRISTINE MARIE | reporter.nih.gov |
| Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $18,362,120 | January 10, 2007 | November 30, 2027 | GULICK, ROY M. | reporter.nih.gov |
| ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $18,205,751 | September 19, 2022 | September 18, 2026 | SAUNDERS, KEVIN | reporter.nih.gov |
| UCSD Collaborative Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $18,116,542 | December 1, 2024 | November 30, 2027 | WILKIN, TIMOTHY J. | reporter.nih.gov |
| The University of North Carolina Center for AIDS Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $18,001,859 | August 20, 2001 | May 31, 2027 | SWANSTROM, RONALD I | reporter.nih.gov |
| Cancer Center Support Grant P30 | NIH | National Cancer Institute | 2021 to 2025 | $17,994,069 | July 1, 2002 | June 30, 2026 | LARA, PRIMO N. | reporter.nih.gov |
| NIAID VIROLOGY QUALITY ASSURANCE (VQA) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $17,732,468 | June 21, 2025 | June 20, 2026 | DENNY, THOMAS | reporter.nih.gov |
| Development of Therapeutic Products for Antibacterial Resistant Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $17,380,862 | September 9, 2019 | January 31, 2026 | OSCHNER, URS | reporter.nih.gov |
| Immunologic strategies to prevent congenital cytomegalovirus transmission and disease in rhesus monkeys | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $17,214,484 | July 24, 2019 | May 31, 2029 | PERMAR, SALLIE R. | reporter.nih.gov |
| East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional Consortium | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $17,134,028 | June 1, 2025 | June 30, 2026 | WOOLS-KALOUSTIAN, KARA KAY | reporter.nih.gov |
| ALS Efficiently Networking Advanced Beam Line Experiments (ALS-ENABLE) | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $17,131,931 | September 1, 2017 | August 31, 2027 | ADAMS, PAUL DAVID | reporter.nih.gov |
| Emory-CDC CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,972,899 | December 1, 2024 | November 30, 2027 | KELLEY, COLLEEN F | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component C: Clinical Core | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,914,921 | September 16, 2019 | September 30, 2026 | BERES, WENDELL | reporter.nih.gov |
| International epidemiology Databases to Evaluate AIDS (IeDEA) Southern Africa. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,840,939 | May 1, 2025 | April 30, 2027 | ROHNER, ELIANE | reporter.nih.gov |
| Center for Viral Systems Biology (CViSB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,438,330 | February 1, 2018 | January 31, 2028 | ANDERSEN, KRISTIAN GRAUGAARD | reporter.nih.gov |
| IMMUNE EPITOPE AND ANALYSIS PROGRAM (infectious diseases as result of other diseases) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,428,426 | December 15, 2018 | December 14, 2025 | SETTE, ALESSANDRO | reporter.nih.gov |
| UAB Center for AIDS Research (CFAR) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,269,163 | March 1, 1997 | May 31, 2029 | HEFFRON, RENEE A. | reporter.nih.gov |
| University of Pennsylvania HIV Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,198,927 | February 1, 2007 | November 30, 2027 | FRANK, IAN | reporter.nih.gov |
| Coordination for ARDS, Pneumonia, and Sepsis supporting Training, Organization and Network Efficiency (CAPSTONE) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $16,153,090 | May 1, 2023 | April 30, 2029 | SELF, WESLEY H | reporter.nih.gov |
| Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $16,069,735 | September 22, 2022 | August 31, 2025 | CIRZ, RYAN | reporter.nih.gov |
| Central Africa International Epidemiology databases to Evaluate AIDS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,957,495 | May 1, 2025 | April 30, 2027 | YOTEBIENG, MARCEL | reporter.nih.gov |
| DEVELOPMENT OF A VACCINE CANDIDATE FOR CORONAVIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $15,898,493 | June 1, 2023 | May 31, 2026 | KRAMMER, FLORIAN | reporter.nih.gov |
| Transmission Aerobiology of M. tuberculosis: Genes and Metabolic Pathways That Sustain Mtb Across an Evolutionary Bottleneck | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,828,159 | May 13, 2021 | April 30, 2027 | RHEE, KYU Y | reporter.nih.gov |
| District of Columbia Center for AIDS Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,682,969 | June 1, 2015 | June 30, 2030 | GREENBERG, ALAN EDWARD | reporter.nih.gov |
| MACS/WIHS Combined Cohort Study: Cook County Clinical Research Site (CC_CRS) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $15,678,563 | April 1, 2019 | September 30, 2026 | FRENCH, AUDREY | reporter.nih.gov |
| C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $15,575,398 | July 1, 2024 | May 31, 2026 | NAHID, PAYAM | reporter.nih.gov |
| Therapeutic Editing to Lower PrP in Prion Disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $15,507,691 | May 17, 2023 | April 30, 2026 | VALLABH, SONIA MINIKEL | reporter.nih.gov |
| PERU Clinical Trial Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,506,525 | December 1, 2024 | November 30, 2027 | SANCHEZ, JORGE LUIS | reporter.nih.gov |
| Caribbean, Central, and South America network for HIV Epidemiology (CCASAnet) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,404,946 | May 1, 2025 | June 30, 2026 | CASTILHO, JESSICA L | reporter.nih.gov |
| NIAID Influenza Data Processing and Communication Center: Universal Influenza Vaccine Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,386,477 | April 1, 2021 | March 31, 2026 | BOUR, STEPHAN | reporter.nih.gov |
| University of Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,173,751 | December 11, 2019 | November 30, 2026 | WALD, ANNA | reporter.nih.gov |
| PHRU-Setshaba Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,110,381 | December 1, 2024 | November 30, 2027 | GRAY, GLENDA E | reporter.nih.gov |
| EXERCISE OPTION PERIOD 1 TO PROVIDE SUPPORT FOR TECHNICAL ASSESSMENTS AND PROJECT MANAGEMENT FOR THE NIBIB RAPID ACCELERATION OF DIAGNOSTICS (RADX) IN | NIH | National Heart, Lung, and Blood Institute | 2021 | $14,996,149 | April 15, 2021 | October 14, 2021 | MARINO, MARK | reporter.nih.gov |
| ERC Einstein-Rockefeller-CUNY Center for AIDS research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,951,126 | May 1, 2017 | April 30, 2027 | GOLDSTEIN, HARRIS | reporter.nih.gov |
| Center for AIDS Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,901,919 | April 1, 2005 | July 31, 2030 | TOMARAS, GEORGIA DORIS | reporter.nih.gov |
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $14,810,179 | July 1, 2020 | October 19, 2025 | OCHSNER, URS ARNOLD | reporter.nih.gov |
| HIPC Data Coordinating Center | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $14,760,228 | April 13, 2022 | March 31, 2027 | PETERS, BJOERN | reporter.nih.gov |
| Hispanic Alliance for Clinical and Translational Research (Alliance) | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $14,653,051 | September 2, 2020 | June 30, 2025 | LUCIANO, CARLOS A. | reporter.nih.gov |
| UAB-MISS MACS/WIHS Combined Cohort Study | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $14,601,685 | April 1, 2019 | September 30, 2026 | KEMPF, MIRJAM-COLETTE | reporter.nih.gov |
| REGULATORY MANAGEMENT CENTER (RMC) - Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $14,546,225 | August 1, 2023 | October 31, 2025 | KIRKBY, MATTHEW | reporter.nih.gov |
| Single cell transcriptomic and epigenomic changes during chronic HIV infection and cocaine self-administration | NIH | National Institute on Drug Abuse | 2022 to 2025 | $14,516,969 | June 1, 2022 | March 31, 2027 | ZENG, HONGKUI | reporter.nih.gov |
| CODA: COvid and Diabetes Assessment | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $14,508,027 | July 21, 2023 | June 30, 2028 | ROTHMAN, RUSSELL L. | reporter.nih.gov |
| Task A90: Establishment of a Model of Nipah Virus Infection for Assessment of Medical Countermeasures Efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,497,049 | April 15, 2024 | September 2, 2025 | BEASLEY, DAVID | reporter.nih.gov |
| Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $14,413,637 | April 1, 2019 | September 30, 2026 | KASSAYE, SEBLE G | reporter.nih.gov |
| Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $14,399,999 | March 26, 2024 | February 28, 2029 | SAVIC, RADOJKA | reporter.nih.gov |
| IeDEA Asia-Pacific Research Collaboration | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,360,741 | July 15, 2006 | April 30, 2027 | SOHN, ANNETTE H | reporter.nih.gov |
| Regulatory Affairs Support | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $14,297,275 | July 1, 2022 | June 30, 2026 | HEREDIA, ELIZABETH | reporter.nih.gov |
| University of Rochester Vaccine and Treatment Evaluation Unit (VTEU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,263,529 | December 11, 2019 | November 30, 2026 | FALSEY, ANN R | reporter.nih.gov |
| A prospective study of critical environmental exposures in formative early life that impact lifelong health in rural US children: the New Hampshire Birth Cohort Study | NIH | Office of the Director, National Institutes of Health | 2023 to 2024 | $14,260,643 | September 21, 2016 | May 31, 2025 | KARAGAS, MARGARET RITA | reporter.nih.gov |
| The RADAR cohort study of multilevel Influences on HIV and substance use | NIH | National Institute on Drug Abuse | 2021 to 2025 | $14,251,651 | April 15, 2014 | April 30, 2030 | MUSTANSKI, BRIAN | reporter.nih.gov |
| 1/2 REPRIEVE Extension for Trial Completion | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $14,219,228 | May 1, 2023 | April 30, 2027 | GRINSPOON, STEVEN K. | reporter.nih.gov |
| Kaiser Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,173,633 | December 11, 2019 | November 30, 2026 | JACKSON, LISA A | reporter.nih.gov |
| NIH Tetramer Core Facility for Immunologic and Infectious Disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,150,571 | March 21, 2020 | March 20, 2027 | ALTMAN, JOHN | reporter.nih.gov |
| MACS/WIHS Combined Cohort Study: Brooklyn Clinical Research Site (Bklyn CRS) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $14,117,524 | April 1, 2019 | September 30, 2026 | GUSTAFSON, DEBORAH R. | reporter.nih.gov |
| Caribbean Primate Research Center Program | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $14,084,108 | April 15, 1987 | November 30, 2028 | LOPEZ, MARCOS | reporter.nih.gov |
| Simian Vaccine Evaluation Unit: Maintenance of Nonhuman Primates | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,042,495 | April 1, 2020 | March 31, 2027 | AYE, PYONE | reporter.nih.gov |
| Center for Translational Pediatric Research | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $14,029,666 | July 11, 2017 | June 30, 2027 | TACKETT, ALAN | reporter.nih.gov |
| UNC MACS/WIHS Combined Cohort Study Clinical Research Site | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $13,957,792 | April 1, 2019 | September 30, 2026 | FLORIS-MOORE, MICHELLE | reporter.nih.gov |
| Simian Vaccine Evaluation Unit: Maintenance of Nonhuman Primates | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,765,907 | April 1, 2020 | March 31, 2027 | VILLINGER, FRANCOIS | reporter.nih.gov |
| HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,518,599 | April 1, 2007 | November 30, 2027 | BEKKER, LINDA-GAIL | reporter.nih.gov |
| Metabolic determinants of Mtb virulence, vulnerability and variation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,485,680 | May 1, 2025 | April 30, 2027 | MOODY, DAVID BRANCH | reporter.nih.gov |
| Protective immunity following dengue virus natural infections and vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,429,941 | July 29, 2015 | July 31, 2030 | HARRIS, EVA | reporter.nih.gov |
| THE PURPOSE OF THIS MODIFICATION IS TO ADD MILESTONE 1A, REVISE THE DELIVERABLES FOR MILESTONE 4-10, AND REVISE THE BASE POP TO END ON 1/18/2022. | NIH | National Heart, Lung, and Blood Institute | 2021 | $13,419,752 | June 8, 2021 | December 21, 2021 | MARINO, MARK | reporter.nih.gov |
| Center for AIDS Prevention Studies (CAPS) | NIH | National Institute of Mental Health | 2021 to 2025 | $13,413,640 | September 1, 2001 | August 31, 2026 | JOHNSON, MALLORY O | reporter.nih.gov |
| Trusted Training: Improving Health and Safety Through an All-Hazard Training Approach | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $13,355,376 | September 1, 1992 | May 31, 2030 | FITCH, ASHLEE | reporter.nih.gov |
| Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,340,237 | April 10, 2020 | November 30, 2026 | MULLIGAN, MARK JOSEPH | reporter.nih.gov |
| University of New Mexico Center for Metals in Biology and Medicine | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $13,321,441 | July 1, 2020 | April 30, 2030 | CAMPEN, MATTHEW J | reporter.nih.gov |
| Translational Global Infectious Disease Reseach Center | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $13,280,972 | September 15, 2018 | July 31, 2028 | KIRKPATRICK, BETH DIANE | reporter.nih.gov |
| The Institute for Biomolecular Targeting | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $13,083,143 | May 15, 2016 | May 31, 2027 | MADDEN, DEAN R | reporter.nih.gov |
| Pitt-Ohio State Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,065,770 | February 1, 2007 | November 30, 2027 | RIDDLER, SHARON | reporter.nih.gov |
| MACS/WIHS -CCS | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $12,990,830 | April 1, 2019 | September 30, 2026 | ALCAIDE, MARIA LUISA | reporter.nih.gov |
| Establishment of a SPF Rhesus Macaque Colony | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $12,897,251 | September 30, 2000 | January 31, 2027 | KAUSHAL, DEEPAK | reporter.nih.gov |
| Understanding Influenza and SARS-CoV-2 vaccine responses, in vivo and in vitro | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,884,300 | September 1, 2003 | April 30, 2029 | DAVIS, MARK MORRIS | reporter.nih.gov |
| HEALTH Center for Addictions Research and Cancer Prevention | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2024 | $12,882,144 | September 8, 2020 | April 30, 2026 | BEECH, BETTINA M. | reporter.nih.gov |
| Successful Clinical Response In Pneumonia Therapy (SCRIPT) Systems Biology Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,773,513 | January 17, 2018 | December 31, 2027 | WUNDERINK, RICHARD G | reporter.nih.gov |
| Vanderbilt HIV Clinical Trials Unit (CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,733,650 | February 1, 2007 | November 30, 2027 | HAAS, DAVID W | reporter.nih.gov |
| Case Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,725,521 | December 1, 2024 | November 30, 2027 | YENDEWA, GEORGE | reporter.nih.gov |
| RADXHIV VIRAL LOAD | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $12,723,739 | September 11, 2007 | July 31, 2028 | MANABE, YUKARI C | reporter.nih.gov |
| Collaborative Pediatric Critical Care Research Network | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $12,717,344 | August 13, 2021 | July 31, 2026 | WATT, KEVIN M | reporter.nih.gov |
| Testing Hypothesized Pathways Linking Infection, Physical Activity, Apoe Genotype, And Biological Sex To Low Dementia Prevalence And Reduced Brain Atrophy In Two Native American Populations | NIH | National Institute on Aging | 2022 to 2025 | $12,690,286 | April 15, 2017 | April 30, 2027 | KAPLAN, HILLARD S | reporter.nih.gov |
| Tennessee Center for AIDS Research (TN-CFAR) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,615,712 | April 1, 2015 | June 30, 2030 | KOETHE, JOHN | reporter.nih.gov |
| A Randomized, Double-Blind, Placebo-Controlled Study of LHP588 in Subjects with P. gingivalis-Positive Alzheimer's Disease | NIH | National Institute on Aging | 2025 | $12,591,952 | August 15, 2025 | July 31, 2029 | DETKE, MICHAEL J. | reporter.nih.gov |
| Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,580,221 | June 1, 2025 | May 31, 2027 | SETTE, ALESSANDRO | reporter.nih.gov |
| Single Cell Transcriptomic and Epigenomic Dissection of Opioid and Cocaine Responses in HIV | NIH | National Institute on Drug Abuse | 2021 to 2025 | $12,564,620 | September 1, 2021 | June 30, 2027 | KELLIS, MANOLIS | reporter.nih.gov |
| Development of an Antiviral to Combat Viral Infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $12,480,276 | November 15, 2022 | April 17, 2025 | CHANG, JINHONG | reporter.nih.gov |
| CURE CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,461,433 | January 1, 2007 | November 30, 2027 | SPECTOR, STEPHEN A | reporter.nih.gov |
| Chemical Biology of Infectious Disease | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $12,421,854 | May 15, 2016 | May 31, 2026 | HEFTY, P SCOTT | reporter.nih.gov |
| The Y-SCORCH Data Generation Center at Yale for Single-Cell Opioid Responses in the Context of HIV | NIH | National Institute on Drug Abuse | 2021 to 2025 | $12,331,452 | August 1, 2020 | July 31, 2026 | SPUDICH, SERENA S | reporter.nih.gov |
| Columbia Collaborative HIV/AIDS Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,286,513 | February 1, 2007 | November 30, 2027 | SOBIESZCZYK, MAGDALENA ELZBIETA | reporter.nih.gov |
| AIDS Linked to the IntraVenous Experience (ALIVE) Study | NIH | National Institute on Drug Abuse | 2021 to 2025 | $12,226,379 | January 1, 2014 | May 31, 2030 | MEHTA, SHRUTI H | reporter.nih.gov |
| Trans-omics Integration of Multi-omics Studies for Osteoporosis | NIH | National Institute on Aging | 2021 to 2025 | $12,202,183 | September 15, 2017 | June 30, 2027 | DENG, HONG-WEN | reporter.nih.gov |
| Tulane National Primate Research Center AIDS SPF Breeding Colony Maintenance | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $12,169,635 | July 1, 2017 | June 30, 2029 | RUSSELL-LODRIGUE, KASI E | reporter.nih.gov |
| Tissue and organ specific human B cell immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $12,146,380 | April 1, 2019 | March 31, 2025 | LUND, FRANCES E. | reporter.nih.gov |
| NATIONAL CLINICAL DATA COLLABORATIVE COUNTS (NACDACC) | NIH | National Institute on Drug Abuse | 2024 to 2025 | $12,127,951 | September 30, 2024 | September 29, 2025 | MAYS, GARY | reporter.nih.gov |
| Cincinnati Children's Hospital Medical Center Vaccine and Treatment Evaluation Units (UM1 Clinical Trial Required) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,115,898 | December 11, 2019 | November 30, 2026 | FRENCK, ROBERT WILSON | reporter.nih.gov |
| Center for Redox Biology and Cardiovascular Disease | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $12,065,347 | February 1, 2018 | June 30, 2028 | KEVIL, CHRISTOPHER G | reporter.nih.gov |
| Rustbelt Center for AIDS Research (Case/UHC-Pitt CFAR) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $12,035,397 | April 1, 1997 | April 30, 2027 | KARN, JONATHAN | reporter.nih.gov |
| Human anti-viral immune responses in tissues and circulation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,930,741 | January 1, 2017 | February 28, 2027 | FARBER, DONNA L. | reporter.nih.gov |
| TB-RICC 3.0 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $11,818,694 | April 1, 2023 | March 31, 2028 | ELLNER, JERROLD J. | reporter.nih.gov |
| RADx-Rad Discoveries & Data: Consortium Coordination Center Program Organization | NIH | National Library of Medicine | 2021 to 2022 | $11,803,325 | December 21, 2020 | November 30, 2022 | OHNO-MACHADO, LUCILA | reporter.nih.gov |
| Targeting the B Cell Response to Treat Antibody-Mediated Rejection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,789,092 | August 20, 2021 | May 31, 2028 | KNECHTLE, STUART JOHNSTON | reporter.nih.gov |
| Durable Alteration of the Human Immune system after Infection or Immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,785,761 | June 8, 2009 | May 31, 2029 | CHUNG, RAYMOND T | reporter.nih.gov |
| REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (with Baricitinib) for Long COVID Related ADRD | NIH | National Institute on Aging | 2024 to 2025 | $11,773,020 | January 1, 2024 | December 31, 2028 | ELY, E WESLEY | reporter.nih.gov |
| DEVELOPMENT OF THERAPEUTIC PRODUCTS FOR ENTEROVIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,757,152 | September 1, 2020 | May 31, 2030 | GLENN, JEFFREY | reporter.nih.gov |
| Task A71: Comprehensive In Vivo Screening of Viral Pathogens of Pandemic Potential | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,745,278 | July 18, 2022 | July 17, 2025 | MORREY, JOHN | reporter.nih.gov |
| Development of an Optimized Adjuvanted TB Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $11,645,061 | September 30, 2021 | September 30, 2025 | EVANS, JAY | reporter.nih.gov |
| Health Outcomes around Pregnancy and Exposure to HIV/ARV (HOPE): Extending the Reach of PHACS to Examine Women's Health | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $11,578,258 | September 1, 2020 | June 30, 2026 | WILLIAMS, PAIGE L | reporter.nih.gov |
| Reagent Resource Support Program for AIDS Vaccine Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $11,522,629 | April 8, 2018 | April 7, 2025 | FREMONT, VALERIE | reporter.nih.gov |
| Using Longitudinal Research to Engage African American and Latinx Sexual- and Gender-Minority Youth in the HIV Prevention and Care Continua and Reduce HIV/AIDS-Related Disparities | NIH | National Institute on Drug Abuse | 2021 to 2024 | $11,452,208 | August 15, 2015 | June 30, 2025 | KIPKE, MICHELE D. | reporter.nih.gov |
| WaNPRC Macaca nemestrina SPF Breeding Colony | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $11,361,503 | September 30, 2002 | June 30, 2028 | FULLER, DEBORAH H. | reporter.nih.gov |
| Complement Mediated Remodeling in Pulmonary Vascular Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $11,355,302 | August 1, 2020 | June 30, 2026 | STENMARK, KURT R. | reporter.nih.gov |
| West African Emerging Infectious Disease Research Center (WA-EIDRC) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $11,322,650 | May 21, 2020 | June 5, 2025 | ANDERSEN, KRISTIAN GRAUGAARD | reporter.nih.gov |
| KwaZulu-Natal Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,302,268 | December 1, 2024 | November 30, 2027 | ABDOOL KARIM, QUARRAISHA | reporter.nih.gov |
| Advancing Transplantation Outcomes in Children | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,293,854 | July 1, 2025 | June 30, 2028 | BRISCOE, DAVID M. | reporter.nih.gov |
| Clinical Development of COVID-19 Therapeutics | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $11,286,393 | September 22, 2023 | February 15, 2026 | WANG, STANLEY | reporter.nih.gov |
| Women HIV Cohort Study: HIV infection and treatment among women of reproductive age | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $11,285,317 | September 27, 2019 | August 31, 2025 | ALCAIDE, MARIA LUISA | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,268,155 | September 1, 2020 | March 31, 2027 | MALINOWSKI, FRANK | reporter.nih.gov |
| The Johns Hopkins University-Blantyre Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,246,510 | February 15, 2007 | November 30, 2027 | TAHA, TAHA E | reporter.nih.gov |
| DATA COORDINATING CENTER TO PROVIDE SERVICES TO WORK COLLABORATIVELY WITH THE NATIONAL NEUROHIV TISSUE CONSORTIUM CLINICAL SITES TO PROVIDE MANAGEMENT AND DATABASE CAPABILITIES, SCIENTIFIC EXPERTISE, | NIH | National Institute on Drug Abuse | 2023 to 2025 | $11,232,511 | August 7, 2025 | August 6, 2026 | SHERMAN, SETH | reporter.nih.gov |
| Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplication | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,202,199 | March 15, 2007 | September 21, 2025 | SANNE, IAN MATTHIAS | reporter.nih.gov |
| Revealing the single cell determinants of brain relevant to persistent HIV infection and opioid use disorder | NIH | National Institute on Drug Abuse | 2021 to 2025 | $11,197,081 | September 30, 2021 | July 31, 2027 | RANA, TARIQ M | reporter.nih.gov |
| Mays Cancer Center at UT Health SA | NIH | National Cancer Institute | 2021 to 2025 | $11,193,809 | August 1, 1997 | July 31, 2026 | ZHENG, LEI | reporter.nih.gov |
| UCLA-CDU CFAR | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $11,094,755 | April 8, 2022 | March 31, 2027 | CURRIER, JUDITH S. | reporter.nih.gov |
| Single cell brain transcriptome changes during chronic HIV infection and opiate use in conventional mice | NIH | National Institute on Drug Abuse | 2021 to 2025 | $11,085,606 | May 15, 2021 | July 31, 2026 | KENNY, PAUL J. | reporter.nih.gov |
| Administrative Supplement for the NCI P30 CCSG to extend partnerships with comprehensive cancer control coalitions to study implementation of evidence-based cancer control interventions | NIH | National Cancer Institute | 2021 | $11,079,774 | January 1, 1997 | March 31, 2022 | LYNCH, THOMAS JAMES | reporter.nih.gov |
| Emerging Infectious Diseases Research Centers Coordination Center (EIDRC CC) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $11,018,742 | May 18, 2020 | April 30, 2025 | SEMPOWSKI, GREGORY D | reporter.nih.gov |
| Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $10,977,909 | September 21, 2022 | November 8, 2024 | TOMARAS, ANDREW | reporter.nih.gov |
| Advancing Vaccine Adjuvant Research for Tuberculosis (TB) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $10,964,476 | September 30, 2022 | September 29, 2027 | BRITTON, WARWICK | reporter.nih.gov |
| Johns Hopkins University Baltimore India Clinical Trail Unit (JHUBI CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,947,708 | February 5, 2007 | November 30, 2027 | GUPTA, AMITA | reporter.nih.gov |
| Providence/Boston Center for AIDS Research (CFAR) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,929,611 | September 1, 1998 | June 30, 2028 | BECKWITH, CURT G | reporter.nih.gov |
| NYR-Diabetes Research Center (NYR-DRC) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $10,878,379 | December 1, 1996 | April 30, 2030 | PESSIN, JEFFREY E. | reporter.nih.gov |
| Advanced Development of a Universal Influenza Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,853,574 | September 9, 2019 | April 24, 2025 | LOCHER, CHRISTOPHER | reporter.nih.gov |
| AIDS Clinical Trials Group (ACTG) DMC Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,797,892 | December 1, 2020 | November 30, 2027 | MAGNUS, MANYA | reporter.nih.gov |
| Reagent Program for HIV and other Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,735,388 | October 15, 2023 | January 13, 2024 | RASHID, SUJATHA | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,650,296 | September 9, 2019 | October 31, 2025 | CASPER, COREY | reporter.nih.gov |
| Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations | NIH | National Institute on Drug Abuse | 2021 to 2025 | $10,550,278 | September 30, 2020 | July 31, 2026 | SPRINGER, SANDRA ANN | reporter.nih.gov |
| Administrative Supplement Request for 2025 Systems Biology for Infectious Diseases Annual Meeting | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,511,156 | August 17, 2018 | May 31, 2028 | KROGAN, NEVAN J | reporter.nih.gov |
| Development of Therapeutic Products for Biodefense, AntiMicrobial Resistant (AMR) Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,501,521 | May 17, 2021 | December 31, 2026 | KANE, BRIAN | reporter.nih.gov |
| ICAP Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,475,165 | December 1, 2020 | November 30, 2027 | EL-SADR, WAFAA M. | reporter.nih.gov |
| Development of Therapeutic Products for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,313,540 | September 23, 2016 | March 31, 2026 | HENKEL, TIMOTHY | reporter.nih.gov |
| Nonhuman Primate (NHP) Core Functional Genomics Laboratory for AIDS Vaccine Research and Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,303,422 | July 1, 2019 | June 30, 2020 | GALE, MICHAEL | reporter.nih.gov |
| ADJUVANT COMPARISON AND CHARACTERIZATION | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $10,234,165 | September 1, 2022 | January 1, 2027 | FELGNER, PHILIP | reporter.nih.gov |
| Establish a Public Private Partnership for COVID19 Research | NIH | Office of the Director, National Institutes of Health | 2021 to 2023 | $10,186,691 | May 2, 2020 | February 29, 2024 | ADAM, STACEY | reporter.nih.gov |
| University of Rochester HIV/AIDS Clinical Trials Unit Administrative Supplement | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,156,163 | August 26, 2025 | November 30, 2027 | KEEFER, MICHAEL C | reporter.nih.gov |
| Nonhuman Primate Core Humoral Immunology Laboratory for AIDS Vaccine Research and Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,129,006 | March 30, 2024 | March 29, 2025 | SHEN, SHAUNNA | reporter.nih.gov |
| Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,070,868 | March 15, 2007 | November 30, 2027 | SUPPARATPINYO, KHUANCHAI | reporter.nih.gov |
| Advanced Development of Medical Countermeasures for Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,028,832 | September 9, 2019 | August 11, 2024 | TOMIC, MILAN | reporter.nih.gov |
| Obesogenic origins of maternal and child metabolic health involving dolutegravir (ORCHID) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $9,956,619 | September 25, 2020 | June 30, 2026 | ABRAMS, ELAINE JANINE | reporter.nih.gov |
| Advanced Development of a Multivalent Vaccine Candidate for Lassa Fever | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,931,387 | September 1, 2017 | January 31, 2027 | SCHNELL, MATTHIAS JOHANNES | reporter.nih.gov |
| The Military HIV Research Program (MHRP) Clinical Trial Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,910,676 | December 10, 2013 | November 30, 2027 | ROBB, MERLIN L | reporter.nih.gov |
| The Johns Hopkins University - Uganda Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,910,249 | February 5, 2007 | November 30, 2027 | FOWLER, MARY GLENN | reporter.nih.gov |
| Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,862,919 | March 22, 2022 | February 28, 2027 | FERNANDEZ-SESMA, ANA | reporter.nih.gov |
| Botswana-Harvard T.H. Chan School of Public Health AIDS Initiative Partnership CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,824,534 | February 1, 2007 | June 30, 2025 | LOCKMAN, SHAHIN | reporter.nih.gov |
| Expanded SPF Rhesus Macaque Breeding Colony for AIDS Research | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $9,705,199 | August 1, 2016 | August 31, 2028 | BOHM, RUDOLF PAUL | reporter.nih.gov |
| Center for Modeling Complex Interactons | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $9,684,540 | March 15, 2015 | June 30, 2025 | WICHMAN, HOLLY A | reporter.nih.gov |
| GHESKIO Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,655,243 | February 1, 2007 | November 30, 2027 | PAPE, JEAN WILLIAM | reporter.nih.gov |
| Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $9,640,870 | August 26, 2021 | September 30, 2024 | LIMAYE, ABHIJIT PRAKASH | reporter.nih.gov |
| Expertise in Using Bitter Taste Receptor Blockers to Improve the Palatability of Pediatric Medicines: Blocker Discovery | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $9,584,357 | September 30, 2025 | September 29, 2026 | SILVERA, PETER | reporter.nih.gov |
| Task B1: Phase I Clinical Trial to Evaluate a Therapeutic for Antibiotic Resistant Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,576,633 | May 13, 2021 | January 31, 2025 | BURMAN, BRIDGETT | reporter.nih.gov |
| DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $9,566,206 | September 30, 2023 | September 29, 2026 | EVANS, JAY | reporter.nih.gov |
| NCATS SECURE SCIENTIFIC PLATFORMS ENVIRONMENT SUPPORT FOR THE N3C DATA ENCLAVE, POP 12/25/2020 - 9/27/2021 | NIH | National Institute on Drug Abuse | 2021 | $9,554,920 | December 25, 2020 | September 27, 2021 | ZAVERTNICK, BRIAN | reporter.nih.gov |
| Research Resource for Human Organs and Tissues | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $9,547,294 | January 9, 1989 | June 30, 2027 | BELL, THOMAS J | reporter.nih.gov |
| University of Washington Arboviral Research Network (UWARN) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $9,499,281 | May 22, 2020 | June 5, 2025 | VAN VOORHIS, WESLEY C | reporter.nih.gov |
| The Center for Innovation in Point-of-Care Technologies for HIV/AIDS and Emerging Infectious Diseases at Northwestern University (C-THAN) | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $9,495,667 | September 11, 2018 | July 31, 2028 | ACHENBACH, CHAD J | reporter.nih.gov |
| M-SCORCH: Methamphetamine use disorder data generation center for Single Cell Opioid Responses in the Context of HIV | NIH | National Institute on Drug Abuse | 2021 to 2025 | $9,490,616 | May 15, 2021 | February 28, 2027 | HO, YA-CHI | reporter.nih.gov |
| Yale Head and Neck Cancer SPORE: Overcoming Treatment Resistance in Head and Neck Cancer | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2024 | $9,412,704 | September 22, 2020 | June 30, 2026 | BURTNESS, BARBARA | reporter.nih.gov |
| Miami Center for AIDS Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,391,980 | November 1, 2006 | May 31, 2027 | CHAKRABORTY, RANA | reporter.nih.gov |
| Development of a Novel Therapeutic for Melioidosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,235,577 | September 20, 2022 | September 30, 2026 | ALLEY, M.R.K. (DICKON) | reporter.nih.gov |
| Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,218,182 | August 24, 2022 | July 31, 2027 | BARKER, BRIDGET MARIE | reporter.nih.gov |
| Center for Excellence in Host Pathogen Interactions | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $9,162,682 | May 13, 2016 | June 30, 2027 | BRADLEY, DAVID S. | reporter.nih.gov |
| The Care Ecosystem Response to COVID-19: Accelerating Research on Dementia Care that Meets the Needs of Caregivers and Persons with Dementia during COVID-19 | NIH | National Institute on Aging | 2022 to 2024 | $9,143,854 | June 15, 2022 | May 31, 2026 | POSSIN, KATHERINE LAUREL | reporter.nih.gov |
| HIV Center for Clinical and Behavioral Studies | NIH | National Institute of Mental Health | 2021 to 2025 | $9,131,244 | September 30, 1987 | April 30, 2028 | REMIEN, ROBERT H | reporter.nih.gov |
| COBRE: Eukaryotic Pathogens Innovation Center (EPIC) | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $9,118,734 | July 15, 2022 | May 31, 2027 | MORRIS, JAMES CULVIN | reporter.nih.gov |
| Vendor Audit Support Through the Comprehensive and Rapid Response to NIAID Research Programs (CARRRP) Contract | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $9,114,944 | September 16, 2024 | August 31, 2029 | WRIGHT, TED | reporter.nih.gov |
| Center for Interdisciplinary Research on AIDS | NIH | National Institute of Mental Health | 2021 to 2025 | $9,088,156 | September 30, 2001 | February 28, 2028 | KERSHAW, TRACE S | reporter.nih.gov |
| American Women: Assessing Risk Epidemiologically (AWARE - RFA) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,079,530 | August 18, 2022 | July 31, 2028 | SCHNALL, REBECCA | reporter.nih.gov |
| Digital, Limited Interaction Efficacy Trial of LifeSkills Mobile to Reduce HIV Incidence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,011,446 | March 9, 2021 | February 28, 2027 | MIMIAGA, MATTHEW JAMES | reporter.nih.gov |
| A-Z Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,989,738 | February 1, 2007 | November 30, 2027 | GOEPFERT, PAUL A. | reporter.nih.gov |
| Understanding Risk Gradients from Environment on Native American Child Health Trajectories: Toxicants, Immunomodulation, Metabolic syndromes, & Metals Exposure | NIH | Office of the Director, National Institutes of Health | 2023 to 2024 | $8,902,713 | September 21, 2016 | May 31, 2025 | MACKENZIE, DEBRA | reporter.nih.gov |
| Understanding Risk Gradients from Environment on Native American Child Health Trajectories: Toxicants, Immunomodulation, Metabolic syndromes, & Metals Exposure | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $8,860,022 | September 21, 2016 | May 31, 2030 | MACKENZIE, DEBRA | reporter.nih.gov |
| Maintenance of the SPF Breeding Colonies at Yerkes National Primate Research Center | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $8,820,543 | September 30, 2002 | May 31, 2026 | COHEN, JOYCE KIMBERLY | reporter.nih.gov |
| Development of Therapeutic Candidates for Biodefense, Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $8,743,439 | September 25, 2023 | June 24, 2024 | RAMSTEDT, URBAN | reporter.nih.gov |
| Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Supporting Financial Sustainability, Advanced Methods, and Knowledge Translation | NIH | National Institute on Drug Abuse | 2021 to 2025 | $8,690,640 | July 15, 2015 | April 30, 2030 | SCHACKMAN, BRUCE R | reporter.nih.gov |
| Task V34: Master Cell Banks Manufacturing for Next Generation SARS-CoV-2 Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $8,647,922 | May 15, 2018 | May 14, 2028 | TRUSHEIM, HEIDI | reporter.nih.gov |
| RADX PROGRAM: TECH PROJECT NO 6114 FLUIDIGM ADVANTA DX SARS-COV-2 RT-PCR ASSAY FOR SALIVA | NIH | National Heart, Lung, and Blood Institute | 2021 | $8,580,056 | July 30, 2020 | September 30, 2021 | QUONG, ANDREW | reporter.nih.gov |
| Microbiome, Metabolites, and Alcohol in HIV to Reduce CVD (META HIV CVD) | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $8,561,222 | September 10, 2021 | August 31, 2026 | FREIBERG, MATTHEW S | reporter.nih.gov |
| NCATS SCIENTIFIC AND TECHNOLOGY SUPPORT SERVICES (STSS) | NIH | National Institute on Drug Abuse | 2024 to 2025 | $8,491,687 | September 30, 2024 | January 6, 2025 | MAYS, GARY | reporter.nih.gov |
| Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis Pathobiology | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $8,479,606 | May 1, 2021 | April 30, 2027 | EFRON, PHILIP A | reporter.nih.gov |
| Simian Vaccine Evaluation Unit: Core Activities - Administrative and Technical Support | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,478,988 | April 1, 2020 | March 31, 2027 | LEWIS, MARK | reporter.nih.gov |
| Hyperhydration to Improve Kidney Outcomes in Children with Shiga Toxin-Producing E. Coli Infection (HIKO STEC): A Multinational, Embedded, Cluster, Crossover, Randomized Trial | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,451,589 | September 17, 2021 | August 31, 2027 | FREEDMAN, STEPHEN BRADLEY | reporter.nih.gov |
| International Epidemiology Databases to EvaluateAIDS (IeDEA) Renewal 4 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,392,710 | July 1, 2006 | July 2, 2026 | JAQUET, ANTOINE | reporter.nih.gov |
| FEND for TB supplement to accelerate BLINK X development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $8,340,332 | June 4, 2020 | May 31, 2025 | ELLNER, JERROLD J. | reporter.nih.gov |
| San Francisco Bay Clinical Trials Unit (CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,314,128 | March 2, 2007 | November 30, 2027 | BUCHBINDER, SUSAN | reporter.nih.gov |
| Texas Developmental Center for AIDS Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,282,292 | April 23, 2021 | March 31, 2027 | GIORDANO, THOMAS P | reporter.nih.gov |
| Consortia for Innovative AIDS Research in Nonhuman Primates | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $8,268,168 | May 1, 2016 | April 30, 2022 | BAROUCH, DAN H. | reporter.nih.gov |
| Uncovering HIV/opioid effects in the brain at the single cell level: transcription, chromatin accessibility, and reservoir analysis in the SIV/cART/morphine/rhesus monkey model | NIH | National Institute on Drug Abuse | 2021 to 2025 | $8,243,787 | August 15, 2021 | June 30, 2027 | FOX, HOWARD S | reporter.nih.gov |
| The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,239,326 | January 15, 2008 | November 30, 2027 | GRINSZTEJN, BEATRIZ | reporter.nih.gov |
| Center for American Indian and Rural Health Equity | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $8,200,764 | September 15, 2014 | August 31, 2025 | ADAMS, ALEXANDRA K. | reporter.nih.gov |
| Hazardous Materials Worker Health and Safety Training (U45), Cooperative Agreement | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $8,171,064 | September 1, 1992 | May 31, 2030 | TURCOTTE, DAVID | reporter.nih.gov |
| Disordered Proteostasis as a Driver of Disease in the Aging Lung | NIH | National Institute on Aging | 2021 to 2024 | $8,161,610 | July 1, 2015 | March 31, 2025 | BUDINGER, GR SCOTT | reporter.nih.gov |
| A deep longitudinal analysis of next generation influenza vaccines in older adults | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $8,127,184 | January 1, 2022 | December 31, 2026 | UCAR, DUYGU | reporter.nih.gov |
| Clinical Pharmacology Quality Assurance (CPQA) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $8,119,963 | May 30, 2025 | May 29, 2026 | MORSE, GENE | reporter.nih.gov |
| Comprehensive Resources for HIV Microbicides and Biomedical Prevention: Quality Assurance/ Quality Control (QA/QC) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $8,076,617 | July 15, 2022 | July 14, 2023 | SILVERA, PETER | reporter.nih.gov |
| Human Biomimetics for Mucosal Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,059,968 | March 15, 2015 | May 31, 2027 | ESTES, MARY KOLB | reporter.nih.gov |
| LSUHSC-NO Comprehensive Alcohol-HIV/AIDS Research Center (CARC) | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $8,052,951 | December 1, 1996 | August 31, 2030 | MOLINA, PATRICIA E. | reporter.nih.gov |
| 1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $8,010,367 | September 16, 2020 | August 31, 2025 | BOECKH, MICHAEL J | reporter.nih.gov |
| CHARTER Plus: A resource for cutting-edge research on neurological function and mental health in people with HIV and substance use disorders across the lifespan | NIH | National Institute of Mental Health | 2022 to 2025 | $7,973,681 | February 1, 2022 | November 30, 2026 | LETENDRE, SCOTT L | reporter.nih.gov |
| Implementation Research Strategies for Heart, Lung, and Blood Co-morbidities in People Living with HIV - Research Coordinating Center | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $7,961,623 | September 30, 2020 | August 31, 2025 | SCHECHTMAN, KENNETH B. | reporter.nih.gov |
| Task C16: Production and Development of Schistosomiasis Research Reagents | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,933,000 | February 1, 2023 | January 31, 2026 | MENTINK-KANE, MARGARET | reporter.nih.gov |
| External Quality Assurance Program Oversight Laboratory (EQAPOL) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $7,902,910 | September 30, 2024 | September 29, 2031 | DENNY, THOMAS | reporter.nih.gov |
| Epidemiology and Impact of the HIV, NCD, and Urbanization Syndemic in Africa | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $7,818,042 | February 2, 2021 | January 31, 2027 | CHANG, LARRY WILLIAM | reporter.nih.gov |
| Advanced Development and Clinical Evaluation of an Entamoeba Histolytica Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $7,788,182 | September 21, 2018 | November 22, 2025 | FOX, CHRISTOPHER | reporter.nih.gov |
| A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $7,767,541 | April 15, 2021 | March 31, 2027 | SCHAUBEL, DOUGLAS EARL | reporter.nih.gov |
| Integrating innate and adaptive pathways in vaccine responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $7,762,589 | April 1, 2014 | March 31, 2024 | RAVETCH, JEFFREY VICTOR | reporter.nih.gov |
| Seattle Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $7,698,581 | February 1, 2007 | November 30, 2027 | MCELRATH, MARGARET JULIANA | reporter.nih.gov |
| Augmenting Scientific Discovery and Research Infrastructure in the UAB Regional Biocontainment Laboratory (SEBLAB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $7,660,000 | September 23, 2021 | February 28, 2025 | LEAL, SIXTO MANUEL | reporter.nih.gov |
| FEND for TB | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $7,632,771 | June 4, 2020 | May 31, 2026 | ELLNER, JERROLD J. | reporter.nih.gov |
| Maintenance of an SPF Macaque Breeding Colony for AIDS Research | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $7,568,566 | August 9, 2001 | January 31, 2029 | RUSSELL-LODRIGUE, KASI E | reporter.nih.gov |
| A major contributor of serious multisystem disease in the elderly: varicella zoster virus-induced inflammation | NIH | National Institute on Aging | 2021 to 2023 | $7,526,233 | March 1, 2009 | December 31, 2025 | NAGEL, MARIA ACENA | reporter.nih.gov |
| Small RNAs as Novel Modulators of Microbe-Host Interactions | NIH | National Center for Complementary & Integrative Health | 2021 to 2025 | $7,525,895 | September 1, 2021 | April 30, 2027 | GITAI, ZEMER | reporter.nih.gov |
| Ad26 Based Therapeutic Vaccines for HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,518,476 | May 12, 2020 | April 30, 2027 | BAROUCH, DAN H. | reporter.nih.gov |
| The International URBAN Alcohol Research Collaboration on HIV/AIDS (ARCH) Center | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $7,511,308 | September 10, 2021 | August 31, 2027 | SAMET, JEFFREY H. | reporter.nih.gov |
| SUPPLEMENTAL FUNDS TO PROVIDE RADX INFRASTRUCTURE SUPPORT THROUGH JULY 1, 2021 | NIH | National Heart, Lung, and Blood Institute | 2021 | $7,499,311 | July 2, 2020 | April 30, 2021 | MARINO, MARK | reporter.nih.gov |
| Interactions Between the Microbiome, Immunity and Respiratory Health in Traditional Agrarian and Suburban children | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,471,626 | February 1, 2013 | February 29, 2028 | GERN, JAMES E. | reporter.nih.gov |
| Extended follow-up of randomized participants in the INSIGHT START trial | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $7,453,707 | May 17, 2019 | April 30, 2025 | GRUND, BIRGIT | reporter.nih.gov |
| Single cell determinants of brain in the context of viral persistence in SIV/cART/cocaine non-human primates | NIH | National Institute on Drug Abuse | 2023 to 2025 | $7,434,979 | June 1, 2023 | February 29, 2028 | RANA, TARIQ M | reporter.nih.gov |
| Advanced Development of Vaccines for Filoviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,417,867 | July 21, 2020 | December 31, 2026 | ELDRIDGE, JOHN | reporter.nih.gov |
| Boston Alcohol Research Collaboration on HIV/AIDS - Comorbidity Center (Boston ARCH CC) | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $7,406,307 | September 22, 2021 | August 31, 2027 | STEIN, MICHAEL D | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers STATISTICAL, DATA MANAGEMENT AND COORDINATION CENTER (SDMCC) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,400,390 | September 30, 2025 | September 29, 2026 | BOUR, STEPHAN | reporter.nih.gov |
| Cohort Studies of HIV/AIDS and Substance Use in Miami | NIH | National Institute on Drug Abuse | 2025 | $7,372,834 | September 30, 2025 | June 30, 2030 | BAUM, MARIANNA K | reporter.nih.gov |
| Administrative Supplements for NIAID Regional Biocontainment Laboratories (RBL) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $7,369,853 | September 23, 2021 | February 28, 2025 | ALEM, FARHANG | reporter.nih.gov |
| IGF::OT::IGFEMMES NEIS-V | NIH | Office of the Director, National Institutes of Health | 2021 | $7,315,897 | November 1, 2016 | October 31, 2021 | HAMMEL, KERI | reporter.nih.gov |
| Harmonist: A Scalable Toolkit for Standardizing and Coordinating Data Sharing Across International Research Networks | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,298,694 | May 25, 2016 | April 30, 2027 | DUDA, STEPHANY NORAH | reporter.nih.gov |
| DEVELOPMENT OF VACCINES FOR INFLUENZA USING AN IMMUNO-MODULATOR ADJUVANT AND MULTI-PLATFORM APPROACH | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $7,281,050 | September 30, 2023 | September 29, 2028 | EL-KAMMASH, BRUXANNE | reporter.nih.gov |
| Specific Pathogen Free 18 Baboon Research Resource (SPF18BRR) | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $7,246,135 | August 15, 2017 | April 30, 2028 | HOPKINS, WILLIAM D | reporter.nih.gov |
| EpiCenter for Emerging Infectious Disease Intelligence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $7,215,074 | July 13, 2020 | June 5, 2025 | JOHNSON, CHRISTINE KREUDER | reporter.nih.gov |
| RAPID ACCELERATION OF DIAGNOSTICS (RADX) PROGRAM: TECH PROJECT NO 2375 - MASSIVELY PARALLEL CENTRALIZED AND DECENTRALIZED ULTRAFAST COVID-19INFECTIOUS | NIH | National Heart, Lung, and Blood Institute | 2021 | $7,200,049 | September 30, 2020 | September 29, 2021 | BEEBE, DAVID | reporter.nih.gov |
| The Bacterial and Viral Bioinformatics Resource Center (BV-BRC) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $7,200,000 | July 18, 2024 | June 30, 2029 | STEVENS, RICK L. | reporter.nih.gov |
| MSM and Substances Cohort at UCLA Linking Infections Noting Effects (MASCULINE) | NIH | National Institute on Drug Abuse | 2021 to 2024 | $7,177,379 | September 30, 2013 | April 30, 2026 | GORBACH, PAMINA MAE | reporter.nih.gov |
| Facility Upgrade for the New England Regional Biosafety Laboratory | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $7,162,679 | August 22, 2022 | February 28, 2025 | TELFORD, SAM R | reporter.nih.gov |
| Adjuvant Development of the TLR4 Ligand BECC470s For Use in Influenza, S. aureus, and P. aeruginosa Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $7,143,498 | September 30, 2023 | September 29, 2028 | SORENSON, GREGORY | reporter.nih.gov |
| Elucidating single cell changes in neurogenic brain regions during HIV and cannabinoid exposure | NIH | National Institute on Drug Abuse | 2023 to 2025 | $7,084,951 | May 15, 2023 | March 31, 2028 | NDHLOVU, LISHOMWA C | reporter.nih.gov |
| Alcohol Research Consortium in HIV: Ending the HIV Epidemic through interventions and Epidemiology at the intersection of the alcohol and HIV care Continua | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $7,057,359 | September 10, 2021 | August 31, 2027 | MCCAUL, MARY E | reporter.nih.gov |
| Enhanced Cohort methods for HIV Research and Epidemiology (ENCORE) in the United States | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $7,056,913 | August 9, 2022 | December 31, 2027 | COONEY, ERIN EILEEN | reporter.nih.gov |
| Molecules and Pathways at the Coccidioides Host-Pathogen Interface | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $7,052,234 | January 1, 2022 | December 31, 2026 | SIL, ANITA | reporter.nih.gov |
| TASK ORDER B-15: Model Development and Medical Countermeasure Evaluation | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $7,029,612 | October 24, 2022 | October 1, 2023 | GRIFFITHS, ANTHONY | reporter.nih.gov |
| Adjunctive Azithromycin Prophylaxis for Scheduled/Prelabor Cesarean Delivery | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $6,955,634 | April 1, 2024 | March 31, 2029 | CLIFTON, REBECCA GERSNOVIEZ | reporter.nih.gov |
| ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $6,937,118 | September 30, 2023 | September 29, 2026 | COLLINS, NICOLAS | reporter.nih.gov |
| Production of Pedigreed SPF Rhesus Macaques | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $6,908,065 | September 30, 2000 | January 31, 2028 | OATES, RHONDA S | reporter.nih.gov |
| Molecular and Immunologic Analysis of the Pathobiology of Human Anthrax | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,892,629 | September 15, 2004 | August 31, 2025 | FARRIS, A DARISE | reporter.nih.gov |
| Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism | NIH | National Institute on Drug Abuse | 2021 to 2024 | $6,868,774 | April 1, 2020 | January 31, 2026 | STRATHDEE, STEFFANIE A. | reporter.nih.gov |
| 1/2: AZithromycin Therapy in Preschoolers with a Severe Wheezing Episode Diagnosed at the Emergency Department (AZ-SWED) | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $6,867,462 | September 15, 2020 | December 15, 2026 | MARTINEZ, FERNANDO D | reporter.nih.gov |
| MIST Early Career Scholar Awards in Mucosal Immunology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,835,591 | July 25, 2011 | June 30, 2026 | ARTIS, DAVID | reporter.nih.gov |
| Native-like Envelope Trimer Therapeutic Vaccination for Induction of Broadly Neutralizing Antibodies to Facilitate HIV Functional Cure | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,813,637 | April 14, 2020 | July 31, 2027 | RIDDLER, SHARON | reporter.nih.gov |
| Predicting Caries Lesion Patterns and Trajectories in Underserved Children, from Infancy to Early Adolescence, in Primary Healthcare Settings | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $6,811,911 | September 23, 2011 | March 31, 2028 | FONTANA, MARGHERITA R | reporter.nih.gov |
| DATA AND SPECIMEN HUB (DASH) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $6,809,935 | December 1, 2021 | November 30, 2022 | VAVRECK, DEBRA | reporter.nih.gov |
| The Mutant Mouse Resource and Research Center at The Jackson Laboratory | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $6,802,936 | January 1, 2010 | January 31, 2030 | LUTZ, CATHLEEN M | reporter.nih.gov |
| Increasing financial and health equity among low income black youth and young adults | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2025 | $6,783,115 | September 23, 2021 | April 30, 2027 | LIPPMAN, SHERI ANN | reporter.nih.gov |
| Emerging Infectious Diseases Research Center - East and Central Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,734,930 | June 1, 2020 | June 5, 2025 | NJENGA, M KARIUKI | reporter.nih.gov |
| Development of a COVID-19 Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,733,518 | September 1, 2020 | October 31, 2023 | REED, STEVEN | reporter.nih.gov |
| Lyme Disease: B cell epitope discovery and mechanisms of antibody protection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,722,146 | September 16, 2019 | September 15, 2024 | MANTIS, NICHOLAS J. | reporter.nih.gov |
| B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection - Administrative Supplement | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $6,714,942 | June 1, 2016 | May 31, 2022 | HUNTER, ERIC | reporter.nih.gov |
| TNPRC Regional Biocontainment Laboratory Upgrade for Capacity Building | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,714,363 | September 23, 2021 | February 28, 2025 | RAPPAPORT, JAY | reporter.nih.gov |
| Emerging infections: surveillance, epidemiology and pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,690,286 | May 11, 2020 | June 5, 2025 | WANG, DAVID | reporter.nih.gov |
| Complementing broadly neutralizing antibodies and autologous responses to restrict virus escape and durably suppress HIV-1 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,685,272 | April 11, 2022 | March 31, 2027 | BAR, KATHARINE JUNE | reporter.nih.gov |
| Aurum Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,678,965 | December 1, 2020 | November 30, 2027 | CHURCHYARD, GAVIN JOHN | reporter.nih.gov |
| A Global Syphilis Vaccine Targeting Outer Membrane Proteins of Treponema pallidum. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,678,063 | May 1, 2019 | April 30, 2025 | RADOLF, JUSTIN D | reporter.nih.gov |
| Administrative Supplement for Upgrading the University of Pittsburgh Regional Biocontainment Laboratory within The Center for Vaccine Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,659,737 | August 22, 2022 | February 28, 2025 | DUPREX, WILLIAM PAUL | reporter.nih.gov |
| West African Center for Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,658,566 | June 9, 2020 | June 5, 2025 | WEAVER, SCOTT C | reporter.nih.gov |
| A Foundation for the Oral Microbiome and Metagenome | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $6,653,092 | April 1, 2006 | March 31, 2027 | MARK WELCH, JESSICA LEIGH | reporter.nih.gov |
| Researching Interventions and Implementation Strategies to Evaluate the Health and Development of Children Affected by HIV | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $6,635,347 | September 18, 2025 | August 31, 2030 | JOHN-STEWART, GRACE C. | reporter.nih.gov |
| B Cell Epitope Discovery and Mechanisms of Antibody Protection: Responses to Dengue 4, Powassan, Chikungunya, and Venezuelan Equine Encephalitis Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,634,396 | September 16, 2023 | September 15, 2024 | FREMONT, DAVED | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,612,767 | September 21, 2022 | January 18, 2026 | KRUISWIJK, CORINE | reporter.nih.gov |
| Role of Data Streams In Informing Infection Dynamics in Africa- INFORM Africa | NIH | Fogarty International Center | 2021 to 2025 | $6,610,435 | September 15, 2021 | June 30, 2027 | ABIMIKU, ALASH'LE G. | reporter.nih.gov |
| Leveraging an ongoing longitudinal study of influenza vaccination to define immune signatures of response and risk of infection in older adults >75 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,605,926 | December 9, 2021 | November 30, 2026 | LENG, SEAN XIAO | reporter.nih.gov |
| California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations | NIH | National Cancer Institute | 2021 to 2025 | $6,605,241 | September 12, 2019 | July 31, 2026 | PALEFSKY, JOEL MICHAEL | reporter.nih.gov |
| Administrative supplement to Duke G20 award | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,594,615 | September 23, 2021 | February 28, 2025 | STAATS, HERMAN F | reporter.nih.gov |
| Facility and Building System Upgrades Support for the Howard T. Ricketts Biocontainment Laboratory | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,593,067 | September 16, 2021 | February 28, 2025 | ADAMS, ERIN JUNE | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,592,393 | September 23, 2022 | July 22, 2026 | NORTON, ELIZABETH | reporter.nih.gov |
| Comparative Modeling to Inform Cervical Cancer Control Policies | NIH | National Cancer Institute | 2021 to 2024 | $6,568,988 | September 8, 2020 | August 31, 2025 | KIM, JANE JOOYUN | reporter.nih.gov |
| Task A68: Screening Vaccine (and Other Biologics) Platform Technologies using Coronavirus Mouse Immunogenicity as a Model System | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,550,363 | May 23, 2022 | September 30, 2026 | GRAHAM, RACHEL | reporter.nih.gov |
| An in integrated platform for multiomic analyses of pathogen and host data using scalable public infrastructure | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $6,532,864 | July 18, 2024 | June 30, 2029 | NEKRUTENKO, ANTON | reporter.nih.gov |
| Stellenbosch University Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,524,563 | April 15, 2007 | November 30, 2027 | HESSELING, ANNEKE CATHARINA | reporter.nih.gov |
| Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $6,498,374 | August 1, 2017 | July 31, 2027 | WARE, RUSSELL E | reporter.nih.gov |
| Regional Biocontainment Laboratory (RBL) Upgrade for Colorado State University (CSU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,493,184 | September 23, 2021 | February 28, 2025 | DOBOS, KAREN MARIE | reporter.nih.gov |
| Multi-level Optimization of the Cervical Cancer Screening Process in Diverse Settings & Populations (METRICS) | NIH | National Cancer Institute | 2021 to 2023 | $6,487,883 | April 10, 2018 | March 31, 2025 | HUGHES, AMY E | reporter.nih.gov |
| Creation and Repair of Postreplicative DNA Gaps | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $6,486,544 | May 15, 2019 | July 31, 2028 | COX, MICHAEL M. | reporter.nih.gov |
| Harnessing the power of text messaging to reduce HIV incidence in adolescent males across the United States | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $6,477,724 | September 23, 2021 | December 8, 2027 | YBARRA, MICHELE L. | reporter.nih.gov |
| Coordinating Research on Emerging Arboviral Threats Encoing the Neotropics (CREATE-NEO) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,472,246 | June 1, 2020 | June 5, 2025 | VASILAKIS, NIKOS | reporter.nih.gov |
| Small-molecule activators of STING-signaling as novel adjuvants for flavivirus vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,461,817 | September 30, 2019 | September 29, 2024 | NELSON, JAY | reporter.nih.gov |
| Dissecting the mechanisms of HIV resistance in vivo to broadly neutralizing antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,461,018 | August 9, 2022 | May 31, 2027 | HERSCHHORN, ALON | reporter.nih.gov |
| METABOLIC ALDEHYDES AS IMMUNE EFFECTORS AGAINST TUBERCULOSIS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,434,161 | September 11, 2025 | August 31, 2029 | DARWIN, KATERINA HERAN | reporter.nih.gov |
| Task A82: Murine Models of UTI Caused by Antibiotic-Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,424,343 | July 19, 2023 | February 27, 2025 | GALLACHER, ANTHONY | reporter.nih.gov |
| Combatting AntiMicrobial Resistance in Africa Using Data Science (CAMRA) | NIH | Fogarty International Center | 2021 to 2025 | $6,419,538 | September 15, 2021 | June 30, 2027 | HAPPI, CHRISTIAN T. | reporter.nih.gov |
| University of Washington (UW) Sexually Transmitted Infections (STI) Cooperative Research Center (CRC) - Syphilis Vaccine to Protect against Local and Disseminated T. pallidum Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,406,743 | August 1, 2019 | July 31, 2025 | WALD, ANNA | reporter.nih.gov |
| Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,398,428 | July 1, 2021 | June 30, 2027 | GENGENBACHER, MARTIN ALFONS | reporter.nih.gov |
| Protective Genetic Variants for Alzheimer Disease in the Amish - RENEWAL | NIH | National Institute on Aging | 2022 to 2025 | $6,381,039 | September 1, 2022 | May 31, 2027 | HAINES, JONATHAN L | reporter.nih.gov |
| Effectiveness of Relationship Education for Reducing HIV Incidence in Men Who Have Sex with Men | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,366,745 | April 1, 2021 | March 21, 2025 | NEWCOMB, MICHAEL E | reporter.nih.gov |
| American and Asian Centers for Arboviral Research and Enhanced Surveillance (A2CARES) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,361,142 | July 20, 2020 | May 31, 2025 | HARRIS, EVA | reporter.nih.gov |
| DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $6,359,752 | September 30, 2023 | September 29, 2028 | LAPEK, JENNIFER | reporter.nih.gov |
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,358,495 | July 1, 2020 | July 28, 2026 | BOWLIN, TERRY | reporter.nih.gov |
| Biologically informed design of CD8+ T cell-dependent pre-erythrocytic stage malaria vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,330,175 | February 4, 2021 | January 31, 2026 | KAPPE, STEFAN HI | reporter.nih.gov |
| Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,328,779 | May 4, 2021 | April 30, 2027 | BOYD, STEVEN ARMEN | reporter.nih.gov |
| Mechanisms of Fecal Microbiota Transplant Protection from Recurrent C. difficile | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,326,957 | July 24, 2020 | June 30, 2029 | PETRI, WILLIAM A | reporter.nih.gov |
| Division of Microbiology and Infectious Diseases (DMID) Clinical Materials Services | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,289,517 | September 22, 2017 | September 21, 2021 | KUDRICK, JOHN | reporter.nih.gov |
| DUAL AFFINITY RE-TARGETING (DART) MOLECULES FOR HIV-1 SUPPRESSION | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $6,287,950 | September 15, 2015 | July 14, 2023 | NORDSTROM, JEFFREY | reporter.nih.gov |
| Defining the mechanisms of HIV resistance to bNAbs in humans | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,279,096 | July 5, 2022 | April 30, 2027 | CASKEY, MARINA | reporter.nih.gov |
| Single Cell Transcriptomics of the Cocaine Use Disorder in the Context of HIV | NIH | National Institute on Drug Abuse | 2022 to 2025 | $6,266,450 | June 15, 2022 | March 31, 2027 | CHENG, CHRISTINE | reporter.nih.gov |
| Enhancing immunity to malaria in young children with effective chemoprevention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,263,495 | July 1, 2025 | June 30, 2027 | JAGANNATHAN, PRASANNA | reporter.nih.gov |
| BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERSTASK ORDER TITLE: VACCINES AGAINST FUSOBACTERIUM FOR FAP-AND LYNCH SYNDROME-ASSOCIA | NIH | National Cancer Institute | 2022 to 2024 | $6,227,249 | June 15, 2022 | May 15, 2025 | CLAPPER, MARGIE L. | reporter.nih.gov |
| INSPIRE (INtelligent Stewardship Prompts to Improve Real-time Empiric Antibiotic Selection for Patients): The INSPIRE-ASP Trial for Intra-Abdominal and Skin and Soft Tissue Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,161,229 | June 19, 2020 | May 31, 2026 | PLATT, RICHARD | reporter.nih.gov |
| Prenatal Exposures and Child Health Outcomes: A Statewide Study | NIH | Office of the Director, National Institutes of Health | 2021 to 2023 | $6,156,799 | September 21, 2016 | August 31, 2023 | KERVER, JEAN MARIE | reporter.nih.gov |
| Developing Teixobactin for Respiratory Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,154,703 | March 22, 2021 | February 28, 2027 | HUGHES, DALLAS | reporter.nih.gov |
| Ancillary Studies of NAFLD and NASH in HIV infected Adults | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $6,132,391 | March 21, 2020 | January 31, 2026 | CHALASANI, NAGA P | reporter.nih.gov |
| A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $6,096,179 | September 5, 2023 | June 30, 2028 | SHAPIRO, ROGER L | reporter.nih.gov |
| Design and testing of immunogens to elicit 10E8-like broadly neutralizing antibodies against HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,090,710 | July 8, 2019 | August 31, 2029 | SCHIFFNER, TORBEN | reporter.nih.gov |
| TO IDENTIFY NOVEL ADJUVANT CANDIDATES THAT CAN BE USED TO AUGMENT THE EFFICACY OF HUMAN VACCINES. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,022,974 | September 30, 2019 | April 30, 2026 | CARSON, DENNIS | reporter.nih.gov |
| Metabolic and epigenetic reprogramming of vital organs in SARS-CoV-2 induced systemic toxicity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $6,015,134 | September 17, 2021 | August 31, 2025 | DEB, ARJUN | reporter.nih.gov |
| Charles R. Drew University of Medicine and Science Research Endowment Program | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2025 | $6,000,000 | June 22, 2023 | May 31, 2028 | CARLISLE, DAVID M | reporter.nih.gov |
| Johns Hopkins HIV Clinical Cohort | NIH | National Institute on Drug Abuse | 2021 to 2024 | $5,955,256 | July 1, 2014 | March 31, 2026 | MOORE, RICHARD DOUGLAS | reporter.nih.gov |
| Partnership for Prevention of HPV-Associated Cancers in People Living with HIV: Brazil, Mexico, and Puerto Rico | NIH | National Cancer Institute | 2021 to 2025 | $5,948,066 | September 20, 2019 | July 31, 2026 | ELLSWORTH, GRANT B. | reporter.nih.gov |
| B-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,936,710 | September 16, 2019 | August 31, 2025 | CROWE, JAMES E | reporter.nih.gov |
| Spatial and temporal resolution to dissect cellular circuits controlling intestinal physiology, immunity, and inflammatory pathologies | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $5,934,972 | August 1, 2023 | May 31, 2028 | XAVIER, RAMNIK J | reporter.nih.gov |
| Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,933,702 | April 8, 2021 | March 31, 2027 | SIM, B. KIM LEE | reporter.nih.gov |
| DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $5,907,864 | September 30, 2023 | September 29, 2028 | BURKHART, DAVID | reporter.nih.gov |
| Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $5,882,740 | August 26, 2021 | May 31, 2028 | LIMAYE, ABHIJIT PRAKASH | reporter.nih.gov |
| Defining the impact of drug use on immune function and fitness against HIV-1 | NIH | National Institute on Drug Abuse | 2021 to 2025 | $5,880,000 | May 1, 2021 | April 30, 2026 | SHALEK, ALEX K | reporter.nih.gov |
| Optimizing HIV prevention for high-risk methamphetamine-using men who have sex with men | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $5,855,396 | April 8, 2022 | April 30, 2027 | GROV, CHRISTIAN | reporter.nih.gov |
| Discovery of adjuvants via novel modulation of innate immune pathways for vaccines against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,841,904 | September 30, 2019 | April 30, 2026 | ESSER-KAHN, AARON | reporter.nih.gov |
| Drivers of individual variation in influenza vaccine response and protection from infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,827,282 | July 14, 2022 | June 30, 2027 | COBEY, SARAH | reporter.nih.gov |
| Controlling and preventing Asthma progression and Severity in Kids (CASK) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,781,955 | July 20, 2016 | June 30, 2024 | PHIPATANAKUL, WANDA | reporter.nih.gov |
| TASK B26: COMPREHENSIVE VIRAL SCREENING PANEL. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,766,379 | December 16, 2024 | December 15, 2025 | JULANDER, JUSTIN | reporter.nih.gov |
| Effects of HIV, Cocaine, and Prolonged ART Use on Subclinical Cardiovascular Disease | NIH | National Institute on Drug Abuse | 2021 to 2024 | $5,744,264 | June 1, 2016 | April 30, 2025 | LAI, SHENGHAN | reporter.nih.gov |
| Rational design and efficacy testing of vaccines against HCV | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,737,237 | May 5, 2022 | April 30, 2027 | FUERST, THOMAS R | reporter.nih.gov |
| 1/1: ARREST RESPIRATORY FAILURE DUE TO PNEUMONIA (ARREST PNEUMONIA) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $5,715,477 | September 23, 2019 | August 31, 2025 | LEVITT, JOSEPH ERIC | reporter.nih.gov |
| Structural Genomics Centers for Infectious Diseases: SARS-CoV-2 Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $5,706,284 | September 1, 2017 | August 31, 2022 | SATCHELL, KARLA | reporter.nih.gov |
| Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA) | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $5,703,886 | September 10, 2021 | August 31, 2026 | CROPSEY, KAREN L | reporter.nih.gov |
| Critical Factors Influencing Echinocandin Resistance in Candida glabrata | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,673,964 | August 1, 2014 | July 31, 2028 | PERLIN, DAVID S | reporter.nih.gov |
| Improvements to the Regional Biocontainment Research Facilities at the University of Missouri | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $5,667,997 | September 23, 2021 | February 28, 2025 | LORSON, CHRISTIAN L. | reporter.nih.gov |
| Computational models of naturally acquired immunity to falciparum malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,666,873 | April 1, 2020 | March 31, 2026 | GREENHOUSE, BRYAN R | reporter.nih.gov |
| Improving Neonatal health Through Rapid malaria testing in Early Pregnancy with high-sensitivity Diagnostics (INTREPiD) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,664,388 | April 1, 2022 | March 31, 2027 | TAYLOR, STEVE MYER | reporter.nih.gov |
| NBER Center for Aging and Health Research | NIH | National Institute on Aging | 2021 to 2025 | $5,663,258 | August 1, 1997 | August 31, 2027 | CUTLER, DAVID M | reporter.nih.gov |
| Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,640,067 | August 5, 2022 | July 31, 2029 | STEINBACH, WILLIAM J | reporter.nih.gov |
| Small-molecule inducers of the cGAS/STING pathway as novel adjuvants for flu vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,636,289 | September 30, 2019 | September 29, 2024 | ADOLFO, GARCIA-SASTRE | reporter.nih.gov |
| Defining the viral PTMome: Towards the development of novel antiviral approaches | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,635,000 | September 30, 2021 | July 31, 2026 | GACK, MICHAELA ULRIKE | reporter.nih.gov |
| Nonhuman Primate (NHP) Core Cellular Immunology Laboratory for AIDS Vaccine Research Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,634,048 | June 1, 2023 | May 31, 2024 | KAUR, AMITINDER | reporter.nih.gov |
| Coordinated Oral Health Promotion (CO-OP) Chicago Cohort Study | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $5,607,586 | July 8, 2021 | June 30, 2027 | MARTIN, MOLLY A | reporter.nih.gov |
| Task C08: Maintenance of Black Fly (Simulium Vittatum IS-7) Immature and Adult Stages | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,602,994 | July 10, 2020 | December 31, 2024 | GRAY, ELMER | reporter.nih.gov |
| Task V02: Manufacture of Influenza for Human Challenge Clinical Trials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,587,695 | May 15, 2018 | May 31, 2026 | HASSEL, THOMAS | reporter.nih.gov |
| Exploiting Diversity-Oriented Chemical Synthesis for Combating Chronic Parasitic Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,580,444 | February 8, 2020 | July 31, 2030 | SIBLEY, L. DAVID | reporter.nih.gov |
| Southwest Center for Advancing Clinical and Translational Innovation (SW CACTI) | NIH | National Center for Advancing Translational Sciences | 2025 | $5,574,473 | August 1, 2025 | June 30, 2032 | PANDHI, NANCY | reporter.nih.gov |
| Comparative effectiveness and complications of intravenous ceftriaxone compared with oral doxycycline in Lyme meningitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,573,382 | September 1, 2021 | August 31, 2027 | NIGROVIC, LISE E. | reporter.nih.gov |
| DON in Pediatric Cerebral Malaria: A Phase I / II Dose-Escalation Safety Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,567,850 | June 1, 2025 | May 31, 2027 | POSTELS, DOUGLAS | reporter.nih.gov |
| Cracking the Code of Transgenerational Inheritance of Behavior | NIH | National Institute on Aging | 2021 to 2025 | $5,561,460 | September 30, 2021 | May 31, 2027 | MURPHY, COLEEN TARA | reporter.nih.gov |
| Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,559,114 | June 17, 2020 | January 31, 2027 | WALZL, GERHARD | reporter.nih.gov |
| Cervical, Anal & Oral HPV Persistence/Adolescent Girls | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,549,203 | May 15, 2007 | January 31, 2028 | DIAZ, ANGELA | reporter.nih.gov |
| UAW Hazardous Material Worker Health and Safety Training (U45) | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $5,542,216 | September 1, 1992 | May 31, 2025 | SIVIN, DARIUS D | reporter.nih.gov |
| Pathogen Data Network | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $5,535,500 | September 1, 2024 | June 30, 2028 | DESSIMOZ, CHRISTOPHE | reporter.nih.gov |
| Inter-regional study of transmission, adaptation and pathogenesis of viruses with pandemic potential in Southeast Asia and West/Central Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,526,401 | July 17, 2020 | June 5, 2025 | SAKUNTABHAI, ANAVAJ | reporter.nih.gov |
| Alzheimer’s Disease Related Biomarkers following SARS-CoV-2 Infection | NIH | National Institute on Aging | 2022 to 2025 | $5,518,240 | June 15, 2022 | March 31, 2027 | WISNIEWSKI, THOMAS M | reporter.nih.gov |
| Advanced Development of Vaccines for Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,495,941 | September 9, 2019 | May 31, 2027 | STAERZ, UWE | reporter.nih.gov |
| Small-molecule adjuvants testing pipeline (Influenza) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,486,225 | September 30, 2019 | September 29, 2024 | LEVY, OFER | reporter.nih.gov |
| 1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $5,484,720 | September 20, 2021 | August 31, 2026 | KANER, ROBERT J | reporter.nih.gov |
| DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment Trial | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,484,466 | August 21, 2020 | May 31, 2026 | NAHID, PAYAM | reporter.nih.gov |
| IND-Enabling Studies for Arenavirus Preclinical Candidate | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,459,651 | May 13, 2021 | January 31, 2027 | SOKOLOVA, NADEZDA V | reporter.nih.gov |
| CATCH Healthy Smiles: A cluster-RCT of an elementary school oral health intervention | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $5,458,535 | June 1, 2020 | June 30, 2027 | SHARMA, SHREELA V | reporter.nih.gov |
| Comparative systems biology of apicomplexan cell division | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,447,470 | July 21, 2022 | June 30, 2027 | GUBBELS, MARC-JAN | reporter.nih.gov |
| Phase II, proof-of-concept randomized controlled trial to evaluate dental caries preventive effects of fluoridated bottle water | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $5,443,761 | September 17, 2021 | September 16, 2026 | SLADE, GARY DOUGLAS | reporter.nih.gov |
| Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with men | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,430,840 | April 12, 2019 | March 31, 2025 | LUETKEMEYER, ANNE FREY | reporter.nih.gov |
| THE NNTC COLLECTS, STORE, AND PROVIDE CLINICAL DATA AND WELL CHARACTERIZED BIOLOGICAL SPECIMENS, INCLUDING POST-MORTEM TISSUE FROM STUDY VOLUNTEERS AND/OR ORGAN DONORS WITH HIV AS WELL AS HIV-NEGATIVE | NIH | National Institute of Mental Health | 2023 to 2025 | $5,429,596 | August 23, 2025 | August 22, 2026 | MOORE, DAVID J | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Research Triangle Institute | Research Triangle Park, NC | 42 | $1.08 billion | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 539 | $971 million | 0 | $0 |
| Duke University | Durham, NC | 328 | $939.6 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 201 | $856.9 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 134 | $839.6 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 109 | $795.6 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 475 | $770.5 million | 0 | $0 |
| PPD Development LP | Wilmington, NC | 7 | $707.8 million | 0 | $0 |
| Emory University | Atlanta, GA | 364 | $649.9 million | 0 | $0 |
| University of Washington | Seattle, WA | 425 | $590.2 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 172 | $503.8 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 308 | $493.7 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 355 | $493 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 360 | $489.7 million | 0 | $0 |
| Washington University | Saint Louis, MO | 372 | $451.1 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 357 | $418.7 million | 0 | $0 |
| Yale University | New Haven, CT | 302 | $399 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 178 | $392.9 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 277 | $381.8 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 240 | $373.4 million | 0 | $0 |
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 78 | $369.4 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 99 | $358 million | 0 | $0 |
| Fred Hutchinson Cancer Research Center | Seattle, WA | 64 | $325.3 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 179 | $319 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 205 | $317.9 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 187 | $293.6 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 200 | $291.5 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 273 | $274.6 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 118 | $258.4 million | 0 | $0 |
| Stanford University | Stanford, CA | 175 | $257.2 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 126 | $239.3 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 79 | $239.2 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 153 | $227.8 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 215 | $226.7 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 215 | $225.8 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 151 | $224.5 million | 0 | $0 |
| Technical Resources International, Inc. | Bethesda, MD | 7 | $217 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 51 | $215.4 million | 0 | $0 |
| Family Health International | Durham, NC | 4 | $214.9 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 184 | $212 million | 0 | $0 |
| University of Georgia Research Foundation Inc | Athens, GA | 145 | $200.2 million | 0 | $0 |
| Ohio State University | Columbus, OH | 183 | $200 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 177 | $194.3 million | 0 | $0 |
| University of Florida | Gainesville, FL | 203 | $193.4 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 115 | $190.7 million | 0 | $0 |
| University of Chicago | Chicago, IL | 118 | $184 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 151 | $180.2 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 107 | $170.2 million | 0 | $0 |
| The Emmes Company, LLC | Rockville, MD | 4 | $169.7 million | 0 | $0 |
| Brown University | Providence, RI | 100 | $165.8 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 83 | $163 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 118 | $162.8 million | 0 | $0 |
| University of California at Davis | Davis, CA | 137 | $149.1 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 136 | $147 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 114 | $143.8 million | 0 | $0 |
| George Washington University | Washington, DC | 52 | $143.3 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 33 | $142.8 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 125 | $138.8 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 109 | $137.4 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 127 | $136.4 million | 0 | $0 |
| University of Rochester | Rochester, NY | 111 | $134.8 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 143 | $131.5 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 105 | $125.9 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 78 | $125.8 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 104 | $122.5 million | 0 | $0 |
| American Type Culture Collection | Manassas, VA | 8 | $121.9 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 109 | $117.3 million | 0 | $0 |
| Rockefeller University | New York, NY | 60 | $115.2 million | 0 | $0 |
| Tufts University Boston | Boston, MA | 109 | $114.7 million | 0 | $0 |
| Dartmouth College | Hanover, NH | 61 | $110.3 million | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 80 | $108.1 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 102 | $105.3 million | 0 | $0 |
| Cornell University | Ithaca, NY | 100 | $100.6 million | 0 | $0 |
| Westat, Inc. | Bethesda, MD | 5 | $98.6 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 84 | $98.5 million | 0 | $0 |
| Colorado State University | Fort Collins, CO | 81 | $94.6 million | 0 | $0 |
| La Jolla Institute for Immunology | La Jolla, CA | 34 | $94.1 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 102 | $89.1 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 58 | $87.1 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 77 | $86.8 million | 0 | $0 |
| Wistar Institute | Philadelphia, PA | 31 | $84.8 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 47 | $84.6 million | 0 | $0 |
| Harvard Medical School | Boston, MA | 101 | $83.8 million | 0 | $0 |
| Temple Univ of the Commonwealth | Philadelphia, PA | 68 | $83.1 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 56 | $82.5 million | 0 | $0 |
| SUNY at Buffalo | Amherst, NY | 90 | $79.3 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 77 | $78.5 million | 0 | $0 |
| Texas Biomedical Research Institute | San Antonio, TX | 49 | $78.3 million | 0 | $0 |
| Axle Informatics, LLC | North Bethesda, MD | 8 | $78 million | 0 | $0 |
| Michigan State University | East Lansing, MI | 59 | $76.8 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 71 | $74.1 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 77 | $73.2 million | 0 | $0 |
| SUNY at Stony Brook | Stony Brook, NY | 71 | $71.2 million | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 65 | $69.9 million | 0 | $0 |
| University of Vermont & ST Agric College | Burlington, VT | 43 | $69.8 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 73 | $69.6 million | 0 | $0 |
| J. David Gladstone Institutes | San Francisco, CA | 26 | $68.2 million | 0 | $0 |
| University of New Mexico Health Scis CTR | Albuquerque, NM | 31 | $66.1 million | 0 | $0 |
| Advanced Bioscience Laboratories, Inc. | Kensington, MD | 10 | $64.7 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 48 | $63.9 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 8,704 | $5,869,236,464 | 0 | $0 |
| 2024 | 9,396 | $6,332,235,678 | 0 | $0 |
| 2023 | 9,374 | $6,623,538,688 | 0 | $0 |
| 2022 | 9,502 | $6,653,344,733 | 0 | $0 |
| 2021 | 9,652 | $7,288,418,032 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.